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ABSTRACT 
 
DESIGN AND ASSESSMENT OF SMALL MOLECULES AS FREE RADICAL 
SCAVENGERS AND POTENTIAL MULTI-TARGET THERAPEUTIC AGENTS 
AGAINST ALZHEIMER’S DISEASE, DIABETES AND CANCER 
 
 
 
May 2018 
 
William Horton, B.S., University of Massachusetts Boston 
Ph.D., University of Massachusetts Boston 
 
 
Directed by Professors Marianna and Bela Török 
 
 
Complex diseases such as Alzheimer’s disease (AD), diabetes and cancer are difficult to 
manage with single target treatment approaches and unfortunately, they are wide-spread. 
For example, over 16 million people are expected to have AD in the US by 2050, thus 
new therapeutic approaches have to be developed. Multi-functional drug candidates have 
gained increasing popularity in treating complex diseases. The impact of oxidative stress 
in almost every disease progression makes them essential components in therapies for 
complex diseases. Endogenous systems typically maintain redox homeostasis within the 
cell, but in the diseased state these systems fail to alleviate oxidative stress. 
Supplementation with exogenous antioxidants can boost the endogenous systems and 
maintain redox homeostasis. Therefore, the development of multi-functional drug 
candidates should also include investigations of the radical scavenging activity of the 
compounds screened. 
 v 
 
 
The radical scavenging activity and multi-target profiles of 61 small molecules were 
assessed by three different radical scavenging activity assays. These compounds were 
selected or designed by taking into account the presence of structural motifs common to 
currently used therapeutic compounds. The drug candidates were screened for amyloid β 
(Aβ) oligomer and fibril formation as well as cholinesterase inhibition. In addition, this 
work aims to address the structure-activity relationship (SAR) between experimental 
radical scavenging effect and the structural characteristics of the compounds studied. In a 
continuation of this idea, phenol and aniline model compounds were investigated to 
identify important physicochemical properties such as the bond dissociation energy 
(BDE) and ionization potential (IP). 
 
The work completed here highlights several compounds with multi-functional activity for 
further development. The SAR studies have identified important structural motifs 
responsible and necessary for therapeutic function. These results can be applied to future 
compound design and further support the multi-functional drug development process. 
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CHAPTER 1 
 
INTRODUCTION AND RESEARCH GOALS 
 
1.1 Introduction  
Complex diseases are becoming a burden on our healthcare system. As the World’s 
population lives longer, the percentage of people living with currently incurable diseases 
such as Alzheimer’s disease (AD), diabetes mellitus, or cancer is only increasing. In just 
the United States, over 16 million people are expected to have AD by 20201, 1.5 million 
people are expected to develop either type 1 or type 2 diabetes every year2 and more than 
1.7 million new cancer cases are expected this year with more than half a million cancer 
deaths projected to occur3. More research needs to be done to provide new, more 
effective therapeutic approaches and/or disease management for these devastating 
diseases.  
Alzheimer’s disease is characterized by amyloid plaques and neurofibrillary tangles in 
the brain coinciding with neuronal cell death and loss of cholinergic transmission in the 
brain4. The complex characterization of AD gives rise to a growing sentiment that the 
development of multi-target treatment options could be the right approach. There have 
been extensive research efforts devoted to cholinesterase inhibitors to retain and even 
improve the synaptic transition in the brain5-7, as well as the inhibition of amyloid fibril 
and oligomer formation8,9. Many symptomatic treatments are designed to provide a multi-
target approach to AD, utilizing several compounds in a pharmaceutical cocktail 10-12. 
What if instead of a cocktail of drugs, one compound could inhibit Aβ fibril deposition 
and boost the lifetime of acetylcholine in the brain? 
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Cancer has also become a major focus in drug development. Commonly, many labs focus 
on single areas of interest and treatment rather than the disease as a whole. With the rise 
in gene editing techniques (such as clustered regularly interspaced short palindromic 
repeats (CRISPR) much of the research has moved into understanding the genetic 
components of cancer, with the goal of early identification and targeted drug delivery 
systems to cancer cells with specific identifiers13-16. There are also extensive research 
aims to understand the processes leading up to the transition of a normal cell to a cancer 
cell. Much of the highlight is on the cellular stress as a trigger for mutation and abnormal 
cellular function. Multi-functional drugs must be an integral part of drug discovery going 
forward17. They could allow for less drug interactions and may reduce the overall side 
effects that drugs cause during treatments. My work aims to characterize the multi-target 
ability of several classes of compounds (β-carbolines, hydrazones and hydrazides) to 
provide new insights into their potential therapeutic possibilities. In this work, I also aim 
to develop multi-target drug candidates for managing the underlying pathologies of AD 
or inhibiting the casein kinase II (CK2) holoenzyme controlling cellular proliferation, but 
also focusing on repairing and preventing further damage to the cellular structure with 
antioxidant compounds. 
While oxidative stress is implicated in the pathology of many different diseases, the 
structure-activity relationship (SAR) of antioxidants is not well understood. Efforts are 
mostly focused on natural antioxidants; however, their pharmacokinetic properties are 
less than ideal due to their poor in vivo activity. Thus, free radical scavenging activity of 
the compounds studied was further investigated through SAR in order to identify 
essential structural motifs to provide better radical scavenging activity with improved 
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absorption, distribution, metabolism, and excretion (ADME) properties to these drug 
candidates. 
1.2 Research goals  
1.2.1 β-carbolines as multi-functional drug candidates for Alzheimer’s disease 
As a complex disease, AD needs multi-target treatment options. The amyloid plaque and 
neurofibrillary tangles forming in the brain coincide with neuronal cell death and loss of 
cholinergic transmission. The basic β-carboline skeleton has a relatively extended 
structure that can span the active center of the cholinesterases with a variety of 
hydrophobic units that can interact at the active site. Earlier findings reported by the 
Török group18 led to the development of a set of β-carbolines with an additional aromatic 
ring, either linked directly or via a carbonyl linker, to test the role of molecular flexibility 
on the efficacy of anti-cholinesterase activity. My work aimed to investigate β-carboline 
derivatives as new drug candidates for potential use as cholinesterase and Aβ fibril 
formation inhibitors as well as radical scavengers.  
1.2.2 Hydrazide and nipecotic acid derivatives as multi-functional drug candidates 
Computer aided drug discovery is a growing field19,20. The aim of my collaborative 
project is to develop drugs based on the molecular interactions expected to occur at the 
active site of an enzyme, so that the drug will bind efficiently. Along the same lines as 
the β-carboline project, this work aimed to look into potential new classes of 
cholinesterase inhibitors guided by molecular docking studies. Docking studies were 
conducted with AutoDock Tools (Version 1.5.6) to identify new drug candidates for 
acetylcholinesterase (AChE) inhibition and AD drug discovery. Fourteen compounds 
were identified and developed based on the docking studies, mimicking the electrostatic 
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interactions of donepezil. In this work, the cholinesterase inhibition studies and radical 
scavenging activities of these compounds were investigated.  
1.2.3 SAR study of hydrazones as radical scavenging compounds 
One of the underlying components to many neurological diseases, cardiovascular 
diseases and cancers is the cellular damage caused by excessive amounts free radical 
species. While this may not be the most potent factor in the progression of these diseases, 
it is worth noting that radical species do influence disease progression21,22. Antioxidants 
are an effective way to prevent/repair the damage done by free radical species in the 
body. The human body already has endogenous systems in place to maintain redox 
homeostasis, but we can supplement this system through the consumption of exogenous 
antioxidants in our diet. Many natural antioxidant structures are complex due to their high 
substituent content and dispersed electron conjugation over various ring systems. In this 
work, I aim to assess the relationship between the physicochemical and structural 
parameters of hydrazone derivatives and their radical scavenging activities. The results of 
this study will provide insights into substituent effects on radical scavenging and help 
further the multi-functional drug development process. 
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1.2.4 SAR study on radical scavenging activity of phenol and aniline model 
compounds 
To date, no study has yet linked radical scavenging activity to specific substituents of 
natural antioxidants, other than the presence of the -OH groups23. In an effort to elucidate 
the importance of the substituents on the radical scavenging activity, phenol and aniline 
model compounds were screened through a SAR study. Driven by my earlier hydrazone 
SAR study where the complicated geometries made it difficult to directly correlate 
activity with substituents24, this study focuses on single ring aromatic systems with 
simpler geometries. Using less complex phenol and aniline models, I aim to investigate 
the effects of substituents on the radical scavenging activity of these compounds. 
1.2.5 Hydrazones as multi-functional drug candidates 
The hydrazone structure has already been reported as a suitable backbone for the 
development of multi-functional drugs in a wide variety of areas, from AD to 
antibacterial agents25-27. Cancer research is an extremely important and highly active area 
of biochemical, medical and pharmaceutical developments13-15. In an effort to further 
identify the multi-functional capabilities of the hydrazone structure; this work looks at the 
radical scavenging activity through a SAR study to identify important characteristics of 
hydrazones as antioxidants. Inhibition of an enzyme, CK2, showing increased expression 
levels in all cancer types will be assessed in order to identify a new class of potential 
therapeutic agents. 
1.2.6 Method development of amyloid fibril formation from lysozyme and insulin 
The formation of amyloid fibrils is a hallmark and often a cause of several diseases. In 
order to develop drugs that target fibril formation against these diseases, we need to 
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develop appropriate assays to assess amyloid fibril formation inhibition. There are many 
different procedures for generating various types of amyloid fibrils in vitro28. However, 
the most common methods to generate fibrils use acidic media (pH of 1.5) and often 
extreme temperatures (70 ºC) for the protein to form fibrillar aggregates18,29. These 
methods work well to produce large amounts of amyloid fibrils quickly, but the growth 
conditions required to form these fibrils are often not physiologically relevant. My goal 
was to investigate new methods of amyloid fibril formation using thioflavin T (ThT) 
fluorescence and atomic force microscopy (AFM) imaging to identify reproducible 
physiologically relevant assay conditions. 
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CHAPTER 2 
LITERATURE OVERVIEW AND BACKGROUND 
 
2.1 Definition and role of reactive oxygen and nitrogen species 
Reactive oxygen species (ROS), such as superoxide and the hydroxyl radical, are often 
produced during cellular respiration and in response to cellular stress. The ROS in vivo 
are generated from enzymatic and non-enzymatic metabolic redox reactions; for example, 
superoxide or hydrogen peroxide can be produced from molecular oxygen by xanthine 
oxidase or catalase for example22. Interaction of oxygen with transition metal ions, such 
as Cu2+, Co2+, Ni2+ or Fe2+, can also generate ROS21,22. The ROS generated can further 
react to produce secondary ROS, such as lipid peroxides, which are much longer lived in 
the cell. Reactive nitrogen species (RNS) are generated in response to cellular stress 
(such as oxidative stress or bacterial infection). They are typically derived from an initial 
NO• radical synthesized from arginine by nitrogen oxide synthases (NOSs)22. Table 1 
includes examples of reactive oxygen and nitrogen species, and their structures.  
  
 8 
 
Table 1: The ROS and RNS family include both free radicals and non-radical species. 
The most common examples are depicted here22,30-32.  
 
 
These oxidative species are both crucial for cell survival and reactive enough to cause 
cell death, thus the body needs to maintain balanced levels of oxidized and reduced forms 
of electron carriers in a redox homeostasis33. Over-production of ROS and RNS species 
contributes to the progression of many ailments, such as Alzheimer’s disease, 
Parkinson’s disease, diabetes, aging, cancer and multiple sclerosis (MS)22,32,34-40. Free 
radical species may not be the defining factor of these diseases, but the underlying effect 
radicals have on the progression of diseases is something that cannot be ignored. This 
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section aims to address the fundamentals of redox homeostasis in the human body and 
what is required to maintain that balance. 
2.1.1 Oxidative species and their functions in the body 
Free radicals, at their physiologically relevant concentrations in the body, perform 
functions such as cell signaling and in the immune response, which are essential for 
survival31,32,41-43. The ROS and RNS are typically synthesized by nitric oxide synthase 
(NOS) and nicotinamide adenine dinucleotide or nicotinamide adenine dinucleotide 
phosphate (NAD(P)H) oxidase isoforms22. Hydrogen peroxide is a common oxidative 
species found in cellular systems, with many uses in the cell and its regulation is tightly 
controlled. One of the ways H2O2 acts is through a transient oxidative inactivation of 
protein tyrosine phosphatases (PTPs)44. As long as the PTPs have a catalytic cysteine 
residue, H2O2 converts cysteine to sulfinic acid, which can be reversed in the presence of 
a reducing agent such as glutathione45. This action of H2O2 has been noted with the 
platelet-derived growth and epidermal growth factors to inhibit the activity of the 
corresponding PTPs45,46. It has also been shown that H2O2 activates transcription factors 
in the Nf-κB family46, which lead to the activation of pro-inflammatory genes and cell 
proliferation22,47. It also acts as a signaling molecule for inflammation through phospho-
activation of the p38 mitogen activated protein kinase48 (hyperphosphorylated in brain 
tissue of Alzheimer’s disease patients44) which decreases global phosphatase activity in 
the cell. The p38 mitogen activated protein kinase controls expression of interleukin-1β 
(IL-1 β), an inflammatory cytokine and regulates expression of COX-II and iNOS22,43. 
Inflammation has a key role in a multitude of diseases as well as in the body’s immune 
response to foreign material. The ROS signaling is part of the pathway for many of these 
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reactions. Control of these ROS and ROS-induced secondary messengers are important to 
prevent an overreaction by the immune system. When the redox homeostasis is not 
balanced properly, reactive species react freely with proteins, lipids and nucleic acids and 
may modify their biological function22,32.  
2.1.2 Damage to the body resulting from excessive amounts of oxidative species  
Excessive concentrations of ROS/RNS typically arise from metabolic issues where the 
body cannot maintain the redox homeostasis and begins to produce excessive amounts of 
these species. Age, lifestyle and environmental factors all contribute to oxidative 
stress20,49-52. One of the recent examples of environmental conditions resulting in 
oxidative species damage has been reported in China. There has been a significant 
increase in lung and breast cancer cases that are closely associated with the rapid 
industrialization and changing lifestyle due to smoking, poor diet and obesity52. In such 
conditions, cells are under excessive oxidative stress, which is usually a signal to the cell 
to begin apoptosis to preserve the integrity of the host organism22. Damage from reactive 
species oxidizes lipid membranes, proteins, and nucleic acids53. However, in the 
progression of cancer, the oxidative damage to the DNA may be so great that the cell 
never triggers apoptosis and enters a continuous cell replication state with unchecked 
cellular division54.  
2.1.3 Endogenous defenses against oxidative stress 
To maintain redox homeostasis, the concentration of ROS/RNS in the body is controlled 
by endogenous antioxidant systems. Protective enzymes (e.g. superoxide dismutase, 
catalase, glutathione peroxidase), non-enzymatic peptides/proteins (e.g. glutathione, 
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ferritin, transferrin, ceruloplasmin, albumin), enzyme cofactors and several metabolites 
(Fig. 1) all constitute the endogenous antioxidant defense system in our body32,53,55-58.  
 
Fig. 1: Examples of endogenous radical scavengers. 
 
The modes of action these systems use to maintain the redox homeostasis can vary 
greatly, from controlling the expression of ROS/RNS at the genetic level to repairing 
damage caused by radical species. However, when these systems fail, oxidative stress on 
the cell can lead to drastic changes in cellular form and function, potentially causing an 
even greater production of oxidative species.  
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2.1.4 Exogenous defenses against oxidative stress 
When endogenous antioxidant systems are not effective enough, the body can rely on 
exogenous antioxidants. The exogenous antioxidants act as support systems to boost the 
endogenous defenses. These species have garnered extensive attention as potential 
candidates for preventing and/or treating many diseases58. Exogenous antioxidants are 
usually supplemented by the diet, these include vitamin C, vitamin E, or polyphenols for 
example (Figs. 2 and 3)53,56-59. Polyphenols are the most common class of exogenous 
antioxidants discussed in the literature59-67 due to their high activity, ease of extraction 
from natural sources and high degree of structural variability65-70. Polyphenols (Fig. 3) 
often show excellent in vitro activity; however, their poor bioavailability has limited their 
practical applications for in vivo systems32,40,58,71-75. 
 
Fig. 2: Examples of vitamin radical scavengers. 
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Fig. 3: Examples of commonly identified polyphenolic antioxidant species. 
 
Polyphenols are not the only class of supplementary antioxidants. There are other 
compounds such as betalains (nitrogen containing), beta-carotene, or, lycopene among 
others (Fig. 4)68,73,76. 
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Fig. 4: Examples of non-polyphenolic antioxidant species. 
 
Other properties of antioxidants such as bioavailability, gastric stability and the metabolic 
degradation are just as important as antioxidant activity when developing new exogenous 
antioxidants73-78. A recent report on exogenous antioxidants has attempted to refine the 
pharmacophores identified in these compounds to improve the drug-like properties of 
natural antioxidants through chemical modification57. It is important to note that while 
exogenous antioxidant supplements may help boost the body’s defense against free 
radical species, they can also be harmful. Several studies reported an increase in lung and 
prostate cancer rates with patients taking β-carotene supplements17,79,80. While these 
systems may help us treat diseases, moderation and mechanistic understanding is key in 
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using exogenous antioxidants to restore the balance of redox processes. This work aims 
to provide insight into possible new multi-functional therapeutic candidates with radical 
scavenging properties to combat a variety of pathological symptoms in diabetes and AD.  
2.2 Multi-functional drug development 
Treatment of complicated diseases, such as Alzheimer’s disease, Parkinson’s disease and 
cancer, have traditionally been met with the same approach to any other disease; one 
drug, one treatment81. However, evidence is mounting that multi-functional drugs may 
prove advantageous in the treatment of these multi-faceted diseases82,83. The 
pharmaceutical community has avoided multi-functional drugs due to the increased risk 
of side effects due to non-specific interactions84. Multi-target drugs have become 
increasingly popular since the early 2000s when evidence for their ability to manage 
these complicated diseases began to increase85-87. Twenty-one percent of all approved 
new molecular entities (NMEs) from 2015 to 2017 by the US Food and Drug 
Administration (FDA) were multi-target drugs88. Specifically speaking for many 
neurological diseases, treatment is not necessarily curing the disease, but rather managing 
the symptoms. Tolerance to these drugs may develop over prolonged use of the single 
target medication leading to increased dosage, with the largely unavoidable risk of 
increased side effects. Another option is treating the disease with a drug that does not 
target the same effector85,89,90,91. The same issues have also been identified in the 
treatment of many cancers, where single target drugs that aim to kill cancer cells lead to 
an adaptation of the cells via by-passing the targeted pathway, rendering the treatment 
ineffective91. However, multi-target compounds have the ability to act on several 
different effectors, managing the disease from more than one therapeutic avenue92,93. This 
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reduces the overall risk of side effects due to increased dosage and may also reduce the 
chance of resistance to the drug. Several new multi-target drugs were developed in 2017 
that treat schizophrenia and major depressive disorders94,95,96. Designing multi-target 
drug compounds is a fast-growing field with many compounds no longer being identified 
serendipitously, but through utilizing structural features of different compounds and 
combining them into a single structure96,97. These hybrid drugs are validated through 
numerous models such as QSAR studies98,99, virtual screening for common 
pharmacophores among known ligands96, molecular docking using the 3D structure of a 
protein100,101 and computational methods aiming to look at the physicochemical 
properties of compounds before any in vivo testing. Investigating the multi-target 
capabilities of potential drug candidates is an invaluable tool in the race to develop new 
and effective treatments. 
2.3 Protein misfolding and its connection to various diseases 
There are a large number of protein misfolding diseases that affect the human body, such 
as Alzheimer’s, Parkinson’s, Creutzfeldt–Jakob, and Huntington’s diseases102-104. This 
work focuses on two diseases associated with protein misfolding and oxidative stress: 
Alzheimer’s disease and diabetes mellitus.  
2.3.1 Processes of proper protein folding 
Protein folding can be a complicated process in a cellular environment. As proteins are 
synthesized by the ribosome from mRNA transcripts, there are a few parameters that help 
define protein structure. For many proteins a chaperone molecule is present to help 
ensure that the protein folds into a specific conformation105,106. Hydrogen bonding holds 
together the secondary structure of the protein followed by the tertiary protein structure, 
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which is held together by interactions between the alpha and beta sheets in the secondary 
structures. Features like disulfide bonds, hydrophobic and hydrophilic interactions, as 
well as other intramolecular forces help maintain the folded structure of a protein106,108. 
Finally, the quaternary structure of a protein, which is comprised of multiple subunits, to 
generate a complete, active state of the protein structure. 
Protein folding is a dynamic process with many different structural end points. A protein 
in solution will arrange so that it has the lowest energy conformation available to it, even 
if that folded state is only slightly more stable than the unfolded state106,107,108. If the 
process of forming a favorable conformation requires too much energy, specific cellular 
conditions, or chaperone proteins assist in the folding process, and if those factors are not 
present the protein will likely fold into a different low energy conformation. Many of 
these other conformations will not retain the structures necessary for proper protein 
function and will necessitate that the protein be degraded or re-folded by other proteins. 
It is also possible for proteins that are correctly folded to become misfolded due to 
oxidative damage, changes in the cellular environment, or exposure to other misfolded 
proteins109. 
2.3.2 Alzheimer’s disease 
Alzheimer’s disease (AD) affects approximately 5.5 million Americans, with that number 
expected to increase to 16 million by 20501. The cost associated with AD healthcare in 
2017 was $259 billion, which is likely going to increase as more patients develop AD1. 
As the 6th leading cause of death in the United states and the 5th leading cause of death for 
people 65 and older, there is a desperate need for practical progress in the field1,4. Studies 
show AD is characterized by three primary signs: extracellular plaques (Aβ), intracellular 
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neurofibrillary tangles (tau) and neuronal cell death. The route by which AD leads to 
death can be different depending on the individual and the symptoms such as loss of 
neuronal synapses, oxidative stress, mitochondrial abnormalities, hormonal changes and 
cell cycle anomalies4. As a multi-faceted disease caused by genetic and environmental 
factors, many therapies that are designed for managing AD combat different contributing 
factors in an effort to slow its progression110-116. The most common approaches are based 
on the cholinergic117 and amyloid cascade118 hypotheses4. The following section aims to 
explore a few factors influencing the development of AD and the literature describing 
their current treatment strategies. For the purpose of this work, I will focus on the 
cholinergic and amyloid cascade hypotheses, specifically on the Aβ peptide.  
The Aβ protein is synthesized by processing of the amyloid precursor protein (APP) at 
the membrane of the cell. Cleavage by α-, β- and γ secretases can result in different 
fragments mainly consisting of 40 or 42 amino acid residues (Aβ1-40; Aβ1-42)119. Though 
APP has been identified in cells and its structure is resolved, there is still much unknown 
about its function, with evidence that it may help to induce neuronal growth, 
synaptogenesis, traffic proteins along the axon, transmembrane signal transduction, 
cellular adhesion and calcium metabolism119. Much of this is not fully replicated in vivo, 
and need to be verified. APP is known to be highly prone to linking with sugars and 
advanced glycation end products (AGEs) and derivatized forms can prevent protein 
degradation by blocking chymotrypsin and trypsinogen120.  
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2.3.2.1 Aβ self-assembly inhibition 
Self-assembly inhibitors aim to prevent the formation of neurotoxic oligomeric and 
fibrillar Aβ species in the extracellular space to prevent inflammation and damage to 
neuronal cells. Due to its importance, an extensive amount of reports are available in the 
literature about Aβ self-assembly inhibitors120. Many different classes of compounds 
have been investigated as potential Aβ fibril and/or oligomer formation inhibitors121-135. 
A few examples can be seen in Fig. 5.  
 
Fig. 5: Examples of Aβ self-assembly inhibitors. 
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Unlike enzyme inhibitors, Aβ self-assembly inhibitor interactions with Aβ are not 
completely understood120, even the mechanism of Aβ fibrillogenesis is not yet fully 
uncovered136-138. Recent work by Shankar, G.M. et al. has proposed a model of Aβ 
fibrillogenesis where a ring-like structure is the main oligomer that then self-associates to 
form the various fibril morphologies seen in the literature138. However, more research is 
needed to corroborate this model. These compounds interact with the amyloid monomers 
preventing their aggregation into oligomers or tightly packed fibrils. 
2.3.2.2 Disassembly of Aβ oligomer and fibril species 
There is widespread agreement in the literature that both the oligomers and fibrils of Aβ 
are neurotoxic139-143. Many reports also suggest that the oligomers are more toxic than the 
fibrillar end products142. The Aβ oligomers target glutamate ionotropic receptor AMPA 
type subunit 2 (GluR2)-containing synapses disturbing the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptors, leading to Ca2+ leakage and synaptic 
loss144. In an effort to focus on clearance of already formed Aβ, several disassembly 
agents have been developed8,9 that aim to clear the Aβ oligomers and fibrils in an effort to 
minimize the effect of the protein’s misfolded form on the brain. Several projects have 
been completed to assess the disassembly of pre-formed Aβ fibrils with small 
organofluorine compounds145, chalcones18 and coumarins18. One therapeutic treatment 
investigated has been to drive the soluble oligomer species to form fibrils in an effort to 
prevent further neuronal damage and then focus on clearance of the fibrils with limited 
success146.  
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2.3.2.3 Cholinesterase inhibitors  
Acetylcholine is a neurotransmitter of particular importance to the peripheral and central 
nervous systems and is involved in processes such as learning, memory, sleep and 
stress146. Acetyl and butyrylcholinesterase inhibitors have been investigated as potential 
therapeutic avenues for AD. AD patients have an impaired capability to synthesize and 
transfer acetylcholine (ACh) and butyrylcholine (BuCh)147. Acetylcholinesterase (AChE) 
and butyrylcholinesterase (BuChE) are involved in terminating the neurotransmitter 
signals of ACh and BuCh in the synaptic cleft. The enzymes bind tightly to their 
substrates (ACh and BuCh respectively). Inhibitors such as galantamine and donepezil 
work to reduce the inflammation in the brain and maintain the ACh or BuCh 
concentration in the synaptic cleft to relay the neuronal signals5-7. Dosage of these 
inhibitors must be very well controlled as concentrations that are too high can lead to 
disruption of nerve signals and cause constant stimulation of muscle and nerve cells.  
2.3.2.4 The role of reactive oxygen species in Alzheimer’s disease 
It has been shown that ROS and RNS significantly impact the progression of AD, 
through direct oxidative damage, increase in inflammation from cytokine release, further 
Aβ fibril development (such as from accumulation of AGEs) and cell death by 
apoptosis4,148. Aβ peptides are also able to generate ROS149. With a high fatty acid 
content, oxygen requirement and iron content, the brain is very susceptible to ROS and 
RNS149,150. Metal ions (e.g. Cu2+ and Zn2+) have also been shown to impact the 
progression of AD in the brain due to increased ROS production151.  
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2.3.2.5 Multi-target approaches to the treatment of Alzheimer’s disease 
Alzheimer’s disease is a multi-faceted disease characterized by amyloid plaques, 
neurofibrillary tangles, decreases in synaptic function and decline in memory. It is 
important when treating AD to look for approaches which help to combat the broad 
variety of potential drug targets152. There is a growing sentiment in the literature that the 
more targets the drug interacts with the better the outcome of the treatment will be. Drugs 
like memoquin153, metformin, sulfonylureas, thiazolidinediones, glucagon-like peptide-1 
(GLP-1) agonist and dipeptidyl peptidase 4 (DPP-4) inhibitors152 work though different 
pathways to help combat AD through treatment of severe symptoms and targeting 
underlying conditions to reduce the progression of AD154.  
2.2.3 Diabetes mellitus 
Diabetes affected 30.3 million Americans in 2015, costing the healthcare industry billions 
of dollars a year, e.g. nearly $250 billion in 2012. These numbers are expected to rise as 
around 1.5 million Americans are newly diagnosed with diabetes every year2. These costs 
are not towards curing the disease, but rather for managing it. In an effort to describe the 
treatment regimens, diabetes has been split into two different types depending on insulin 
resistance (type 1: insulin responsive and type 2: insulin resistant)4,155. Glucose control is 
essential for improved short and long-term outcomes with either type156. There are two 
common conditions that develop as a result of poorly treated diabetes: hyperglycemia and 
diabetic ketoacidosis, both of which are fatal.  
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2.2.3.1 Diabetes mellitus type 1 and 2  
Type 1 diabetes is associated with the body’s inability to produce insulin through 
impairment of pancreatic β-cell function. This disease is most often genetic, with several 
different genetic mutations currently noted for patients with type 1 diabetes155. Due to the 
nature of type 1 diabetes, it is not relevant to my work and will not be further discussed. 
Type 2 diabetes is non-insulin dependent (or typically termed insulin – resistant) and 
makes up approximately 90% of the diabetes cases157. For patients with type 2 diabetes, 
managing their disease is much more complicated. It is not as simple as injecting insulin, 
but also requires managing the different factors contributing to their disease progression. 
Obesity, poor diet and poor exercise are all contributing factors to the development of 
type 2 diabetes. As rates of obesity increase across the World, type 2 diabetes rates have 
also increased158. Damage caused through poor management of type 2 diabetes can 
damage from the pancreatic β cells and the patient can develop type 1 diabetes.  
For many type 2 diabetes patients, the current treatment is the same as for type 1 patients: 
insulin. High doses of insulin help control blood glucose levels preventing hyperglycemia 
but can increase the body weight of patients and put them at risk for heart failure159. 
Gluconeogenesis is a common cause of hyperglycemia in patients and inhibiting FBPase 
prevents endogenous glucose production160. The enzyme FBPase catalyzes the hydrolysis 
of fructose 1,6- bisphosphate to fructose 6-phosphate and is the rate limiting step of 
gluconeogenesis161. There are three main classes of inhibitors for FBPase: substrate site, 
subunit interface and AMP site binding inhibitors. Indole, benzimidazole, pyrrole and 
triarylpyrazoles derivatives have been investigated as allosteric inhibitors acting at the 
AMP binding site of the enzyme162-164. These compounds are all designed to mimic AMP 
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in the binding site of the enzyme, to provide better inhibition profiles with FBPase and 
reduce the presence of phosphate groups in these compounds to reduce the possibility of 
non-specific inhibition of other AMP binding enzymes. Glucagon like peptide-1 (GLP-1) 
receptor agonists (which boost signal to produce more insulin) or dipeptidyl peptidase 4 
(DPP-4) inhibitors which block the degradation of normal GLP-1 have also been used to 
treat type 2 diabetes165. As an alternative method, sodium–glucose co-transporter 2 
inhibitors have also been used to prevent hyperglycemia by blocking the reabsorption of 
glucose by the kidneys165. There have been other efforts to look at antioxidants as 
therapeutics for type 2 diabetes as there is evidence that the increase of ROS species 
(such as H2O2) in the mitochondria can lead to insulin resistance159. Antioxidant 
supplementation has been shown to increase glucose tolerance and insulin sensitivity159. 
  
2.2.3.2 Diabetes and its possible connections to Alzheimer’s disease 
Recent evidence suggests that there may be a connection between type 2 diabetes and 
AD4,166-168. Gut and muscle tissue insulin is routinely investigated in the literature, but it 
is also present in the brain (transported from the pancreatic β-cells and may even be 
synthesized in the brain4,169-172. With the increased insulin production in type 2 diabetes 
patients, they have an elevated insulin level in the brain. Increases in insulin levels alter 
the metabolism of amyloid beta and tau, causing increases in the levels of extracellular 
Aβ1–40 and Aβ1–42 as well as APPα in cultures of rat cortical neurons and mouse 
neuroblastoma cells overexpressing wild-type APP173,174. Insulin degrading enzyme 
(IDE) clears out extracellular Aβ in healthy patients, but due to the high binding affinity 
for insulin it becomes inactive in patients with type 2 diabetes175. Aggregation of Aβ and 
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tau leads to inflammation in the neuronal cells and changes in the cellular structure that 
further drive amyloid aggregation in the brain151. Insulin fibril formation has also been 
shown to promote Aβ fibril formation as well as tau phosphorylation in neuronal 
cells176,177. Combined with the effects on increased insulin concentrations in the brain, 
this will lead to further AD progression.  
A third aspect of the effect of diabetes on the development of AD is the increased 
production of ROS and RNS. Insulin resistance decreases the number of GLUT4 
transporters in the plasma membrane, decreasing the amount of glucose available to the 
neuronal cells, leading to hyperglycemia4. The lack of glucose will lead to mitochondrial 
overload, from processing fatty acids and protiens156, increasing the oxidative stress in 
the cell.  
2.4 Cancer 
Cancer is a multi-faceted disease with genetic components, environmental factors and 
physiological contributions that lead to the initialization and progression of cancer in a 
patient. There has been a significant amount of work published on understanding the 
genetic components to different types of cancer13-16, but there are many underlying 
physiological problems which also contribute to the development of cancer in an 
individual.  
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2.4.1 Reactive oxygen species and cancer development 
As cancer cells develop, their metabolism shifts from the complex oxidation of glucose to 
CO2 toward lactic acid production even under aerobic conditions in a process known as 
the Warburg effect178-181. The ROS and RNS species play a huge role in cancer 
development. Increased levels of ROS and RNS are central to the progression of most, if 
not all cancers. Improper redox homeostasis and overall metabolic irregularities, among 
other things, create excessive amounts of ROS and RNS in the cell182,183. As discussed in 
section 2.4.1, ROS and RNS have dramatic effects within the cell. Constant exposure to 
the elevated levels of oxidative stress and cellular inflammation lead to irreparable 
damage to the cell and can push the cell to become cancerous182,184,185. Antioxidants have 
been shown to help combat this progression towards cancer at early stages182. However, 
ROS are involved in pathways promote cell survival or induce apoptosis183,184. Redox 
homeostasis in cancer cells is elevated compared to that of normal cells, but it appears 
there is still a balance to the increased ROS production, where increasing the ROS 
concentration further leads to cellular death. Cancer cells are able to produce slowly 
dividing cells that survive processes such as chemotherapy185. They have elevated 
antioxidant systems that allow the cells to lower the ROS concentrations in the cell and 
keep them in a stable state. Reduction of ROS levels, through antioxidant 
supplementation, in cancer cells results in a loss of adhesion of molecules on the surface 
of the cell and can turn a cancer malignant182. Treatment of cancer cells with antioxidants 
may in fact advance the cancer development resulting in metastasis. 
While antioxidants may help protect patients from cancer in some cases, they have also 
been shown to promote cancer growth80. A common treatment of cancer is to increase the 
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ROS concentrations in the cells to such a high level that it triggers apoptosis. A 
pancreatic cancer treatment is a combination of gemcitabine with trichostatin A, 
epigallocate-3-gallate (EGCG), capsaicin and benzyl isothiocyanate (BITC)184,186-189 
which work to increase the ROS concentrations in cells and trigger apoptosis. 
Chemotherapy is used to induce mutations in the mitochondrial DNA to induce higher 
ROS formation rates leading to cellular apoptosis182,190. Targeting ROS production in 
cancer cells provides new mechanisms into combating the generation or continued 
proliferation of cancer in the body. Understanding ROS involvement in cancer cell 
development and progression, as well as its usefulness in therapeutic approaches, is 
important for the development of future treatments.  
2.4.2 Casein kinase II  
Casein kinase II (CK2) is a ubiquitous serine/threonine kinase, which has been shown to 
influence cell survival, growth and death191-193. It is a holoenzyme (130–150 kDa) 
consisting of 4 subunits one CK2α (42 kDa), one CK2α’ (38 kDa) and two CK2β (26 
kDa) subunits that can maintain different configurations of subunits forming a α2β2, 
αα’β2, or α’2β2 complexes191,194. The CK2α subunit is 90% similar to CK2α’ at its 
catalytic site but they are derived from different genes. Interestingly, only CK2α and 
CK2β have been shown to be essential for cell survival192. More importantly, CK2 can 
suppress apoptosis, leading to cell survival192,193,195. It is no surprise that CK2 
deregulation, resulting in elevated CK2 expression, has been identified in many cancer 
phenotypes192,195-201. Due to the different chemical composition of cell types and the 
ubiquitous presence of CK2, it only makes sense that CK2 potentially has a large variety 
of substrates202 and different modes of action, such as inhibiting apoptosis through 
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phosphorylation of proteins193, 195, 203-208 or suppressed expression of the NF-κB 
complex191. There has been a significant amount of research published on potential 
inhibitors of the CK2 holoenzyme. For example, flavanone-based inhibitors have been 
investigated due to their ease of extraction from natural sources and their potential 
activity as free radical scavengers, which makes them possible multi-functional drug 
candidates (Fig. 6)209-211. The most potent flavanones have at least two hydroxyl groups 
located at positions 7 and 4′ 209. 
 
Fig. 6: Flavanone derivative CK2 inhibitors. 
 
Multi-functional drugs are useful in the field of drug development; however, it is 
important that the active compounds identified are selective inhibitors of only the 
enzymes targeted. For this reason, other protein kinases are screened to ensure selectivity 
of the inhibitor. One of the most common types of inhibitors for CK2 identified acts at 
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the small ATP binding pocket of the enzyme, such as emodin212, emodina213, 4,5,6,7-
tetrabromo-1H-1,2,3-benzotriazole214, 4,5,6,7-tetrabromo-2-
(dimethylamino)benzimidazole215 and 5-oxo-5,6-dihydro-indolo(1,2-a)quinazolin-7-
yl]acetic acid210. There are other inhibitors such as 1,3-dichloro-6-[(E)-((4-
methoxyphenyl)imino)methyl]dibenzo(b,d)furan-2,7-diol, 1,8-dihydroxy-4-nitroxanthen-
9-one, 8-hydroxy-4-methyl-9-nitrobenzo[g]chromen-2-one and 3,8-dibromo-7-hydroxy-
4-methylchromen-2-one which have potent and selective inhibition activity against CK2 
with IC50 values in the nM to µM range (Fig. 7)206,216. Several anthraquinones, 
xanthenones and coumarins have been shown to be potent inhibitors of CK2. A defining 
factor of many of these inhibitors is the presence of hydroxyl, nitro, amino, or halogen 
substituents, which may interact with the enzyme at the ATP binding site, or act via other 
possible modes of inhibition216.  
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Fig. 7: Examples of CK2 holoenzyme inhibitors. 
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CHAPTER 3 
TECHNIQUES AND METHODOLOGIES 
 
3.1 Cholinesterase inhibition assay using Ellman’s method 
Originally described by Ellman et al.,217 the Ellman’s method monitors the activity of 
cholinesterase enzymes through the use of an indicator (5,5'-dithio-bis-[2-nitrobenzoic 
acid] or DTNB) and UV-Vis spectroscopy. The Ellman’s method for cholinesterase 
inhibition works with both acetyl and butyrylcholinesterase enzymes, monitoring the 
overall activity of the enzyme as it works to hydrolyze the respective substrates 
(acetylthiocholine and butyrylthiocholine) to acetic acid or butyric acid (depending on the 
substrate and enzyme) and thiocholine (Fig. 8).  
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Fig. 8: Hydrolysis of acetyl and butyrylthiocholine by cholinesterases.  
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The indicator, DTNB, reacts with the free sulfhydryl groups of thiocholine, forming a 
yellow product which is monitored with UV-vis spectroscopy at 415 nm (Fig.9). During 
the assay, the kinetics of the absorbance increase is periodically measured for 15 min. 
 
 
Fig. 9: DTNB reaction with thiocholine produced by the cholinesterases. 
 
This method allows a comparison of rates of enzymatic reactions observed when carried 
out in conjunction with an uninhibited control group and a control group with known 
inhibitors (such as galantamine and donepezil). The ratios of DTNB to substrate must be 
tightly controlled, since DTNB concentrations higher than ACh has been shown to inhibit 
cholinesterase activity and is likely related to inhibition of the enxyme218. The DTNB is 
also sensitive to sunlight and must be protected from light prior to performing the 
assay219. The Ellman method provides a rapid and efficient profile of the inhibition of test 
compounds against cholinesterase enzymes.  
3.2 Determination of radical scavenging activity of small molecule antioxidants  
There is a broad assortment of currently used radical scavenging and antioxidant capacity 
assays in the literature21,220. With so many different assays and experimental conditions 
used, it is often difficult to accurately compare the literature data from different 
laboratories. High in vitro activity of samples does not necessarily correlate to the same 
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level of in vivo antioxidant activity21. This issue is further complicated by the varying 
routes that antioxidants go through to scavenge radical species in solution. Three 
common mechanisms of radical scavenging are illustrated in Fig. 10.  
 
Fig. 10: Three common mechanisms for radical scavenging in solution by antioxidant 
species.  
 
The HAT mechanism is based on a hydrogen atom transfer from the scavenger to the 
radical species in solution, forming a more stable radical from the antioxidant and 
quenching the radical species in solution220,221. This transfer is an adiabatic process 
involving the transfer of the hydrogen atom (proton and an electron) in the same step. 
The SET mechanism is somewhat more complicated. The end result of SET is similar to 
that of the HAT mechanism220. However, electron transfer is the first step here, followed 
by the transfer of the proton. The rate limiting step of this reaction is the electron transfer 
and this mechanism is often mistaken for the HAT mechanism if the proton transfer is 
rapid. 
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The third common mechanism discussed here is the SPLET mechanism. This mechanism 
is significantly different than the previous two mechanisms. Here, the antioxidant first 
loses a proton to the solvent in solution. Next, the radical scavenger donates an electron 
to the radical species followed by the radical abstracting a hydrogen from an adjacent 
source220. The rate limiting step of this reaction is the electron transfer, which relies on 
the stability of the antioxidant after this step of the reaction. 
The different scavenging mechanisms, kinetic activities and various solvents may have 
effects on the measured radical scavenging activity of the compounds studied. As such, 
different radical scavenging assays are used to provide a more comprehensive idea of 
how the compounds investigated act as free radical scavengers21,220. Control antioxidant 
compounds Trolox (a water-soluble analog of vitamin E), resveratrol (a natural 
antioxidant found in plants such as grapes or blueberries) and ascorbic acid (also known 
as vitamin C) were used for comparison and to ensure the radical scavenging assays were 
carried out properly (Fig. 11).  
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Fig. 11: Structures of known antioxidants used as control compounds for the radical 
scavenging assays (DPPH, ABTS and ORAC). All compounds were applied at 10 μM 
concentration for each assay.  
 
Here, three standard free radical scavenging assays are used to determine the antioxidant 
capacity of the compounds. The following three assays were chosen for their simplicity, 
common occurrence in the literature, solubility of the compounds and reproducibility. 
3.2.1 DPPH radical scavenging assay  
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay is commonly reported in the 
antioxidant literature. It examines the radical scavenging activity of a compound as it 
scavenges the DPPH radical. It is a commercially available stable radical species. The 
assay is typically performed in methanol or ethanol, but it has also been carried out in 
water / alcohol mixtures, such as 50% aqueous ethanol21,24,220,222. The DPPH absorbs in 
the UV-Vis range at approximately 519 nm wavelength, with the decline in absorbance 
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recorded as compounds scavenge the radical. In solution, the color changes from the 
oxidized DPPH (purple) to reduced DPPH (yellow) (Fig. 12).  
 
Fig. 12: The net chemical reaction of the DPPH radical scavenging assay.  
 
The antioxidant scavenges the purple DPPH radical converting it to its non-radical form, 
which is yellow in color. A loss of absorbance is monitored at a wavelength of 519 nm. 
Percent radical scavenging was determined using Eq. 1.  
[Eq. 1] 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑎𝑑𝑖𝑐𝑎𝑙 𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 = (஺௕௦೎ି஺௕௦೟)
஺௕௦೎
 𝑥 100              
Absc is the control absorbance of the DPPH alone. Abst is the absorbance of the DPPH 
with the test compound. 
 
The DPPH assay requires time to complete, with some studies running the assay from 30 
min to 24 h. The interaction between the radical and radical scavengers can vary 
significantly depending on the solvents used and the form of the radical scavenger 
(extracts or single compounds). In my work, readings were recorded every 15 min for 1 
h, but the 30 min readings were determined to provide the least significant variation in 
the data while also allowing for sufficient time to scavenge the radical. The DPPH assay 
is a mixed mode assay and is effective primarily with compounds that act through the 
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SET and HAT mechanisms, depending on the antioxidant’s mode of action and solvent 
effect21.  
3.2.2 ABTS radical scavenging assay  
The 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (or Trolox 
equivalence antioxidant capacity (TEAC)) assay utilizes the ABTS radical generated 
prior to its use by reaction with an oxidizing agent (such as: K2S2O8)21,220. The ABTS 
radical is green in color and absorbs in the UV-Vis range at approximately 734 nm. 
Percent radical scavenging was determined using Eq. 1.  
[Eq. 1] 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑎𝑑𝑖𝑐𝑎𝑙 𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 = (஺௕௦೎ି஺௕௦೟)
஺௕௦೎
× 100   
Absc is the control absorbance of the ABTS alone. Abst is the absorbance of the ABTS 
with the test compound. 
           
 
As the ABTS radical is scavenged, the non-radical product turns colorless. Thus, the 
decrease in the absorbance appears to be related to the antioxidant capacity of the sample  
(Fig. 13).  
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Fig. 13: The chemical reaction of the ABTS radical scavenging assay. The antioxidant 
scavenges the green ABTS radical converting it to its non-radical form, which is 
colorless. A loss of absorbance is monitored at 734 nm. 
 
This assay was originally developed for standardization of the antioxidant activity of 
plant-based extracts, reporting the results in Trolox equivalence amounts. This was meant 
to give the scientific community working with plant-based extracts a way to standardize 
and compare the results obtained in different labs. Unlike other radical scavenging 
assays, the ABTS assay requires 12 min to complete, with readings taken at 0, 6 and 12 
min, as the interaction between the radical and radical scavengers is complete within 12 
min. 
The ABTS assay is a mixed mode assay and is effective primarily with compounds that 
act through the SET and HAT mechanisms, depending on the antioxidant’s mode of 
action21.  
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3.2.3 ORAC radical scavenging assay  
The oxygen radical absorbance capacity (ORAC) assay has been widely used to analyze 
the antioxidant capacity of food samples. It uses the 2-hydroperoxy-2-
methylpropanimidamide radical that is much smaller than the DPPH and ABTS radicals. 
The antioxidant scavenges the peroxyl radical generated by the reaction of AAPH with 
O2 and is converted to its peroxide form (Fig. 14).  
  
Fig. 14: Preparation of the radical and its quenching by the antioxidant in the oxygen 
radical absorbance capacity (ORAC) radical scavenging assay.  
 
By scavenging the peroxyl radical, the fluorescein dye is unaffected and continues to 
fluoresce. The lack of antioxidant activity allows the radical to oxidize the dye and thus 
decrease the fluorescence. The sample is getting excited at 485 nm and the loss of 
fluorescence is monitored at 520 nm over the course of 60 min. 
The ORAC assay was conducted at a concentration of 0.612 µM fluorescein and 19.125 
mM AAPH with the compound concentration of 10 µM and screened at an excitation and 
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emission wavelength of 485 and 520 nm respectively. Fluorescent intensity was 
calculated by Eqs. 2 and 3.  
[Eq. 2] 𝑁𝑒𝑡 𝐴𝑈𝐶 = 0.5 + ∑ ௙೔
௙బ
+ ቀ0.5 ∗ ௙యబ
௙బ
ቁ଴ିଶଽ           
The parameters are defined as followed: fi is the fluorescence intensity at reading 1 
to 29, f0 is the initial fluorescence intensity at reading zero and f30 is the 
fluorescence intensity at reading 30. 
 
[Eq. 3] 𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑅𝑎𝑑𝑖𝑐𝑎𝑙 𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 = (ே௘௧ ஺௎஼೟ିே௘௧ ஺௎஼೎)
ே௘௧ ஺௎஼೑_೘ೌೣ
× 100 
Net AUCc is the net area under the curve as defined in Eq. 2 in case of the control with 
fluorescein and radical. Net AUCt with the test compound. Net AUCf_max with the 
fluorescein alone. 
         
This assay is effective primarily with compounds that act through the HAT mechanism 
for free radical scavenging21,223. Originally, the ORAC assay was developed to use β-
phycoerythrin (β-PE) fluorescent protein isolated from Porphyridium cruentum as the 
fluorescent probe oxidized by 2,2′-azobis(2-methylpropionamidine) dihydrochloride 
(AAPH)224,225. However, the fluorescence decay of β-PE fluorescent protein was too 
quick and it was eventually replaced with fluorescein to provide better long term stability 
of the fluorescent probe (Fig. 15)228.  
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Fig. 15: Fluorescein is the fluorescent probe currently used to detect the AAPH radical in 
the ORAC assay.  
 
This procedure was modified for high-throughput studies using a COBAS FARA II 
analyzer to provide larger sets of data. The automation of the ORAC assay allowed for 
the assessment of the length of radical scavenging activity and antioxidant capacity 
through kinetic measurements of many different samples at a time21. The ORAC readings 
can be further processed in comparison with a Trolox dilution series21. By standardizing 
the results, the data collected will be comparable to other data in the literature. The 
ORAC is a useful tool in the arsenal of free radical scavenging assays to analyze the 
activity of single compounds and plant derived extracts. The ORAC assay has been 
shown to provide higher activity readings to radical scavenging compounds with slower 
kinetic profiles220.  
3.3 In vitro protein fibril aggregation 
Protein structure is a string of amino acids that are arranged in a three-dimensional space 
by various inter- and intra-molecular forces such as hydrogen bonding, disulfide bonds 
and hydrophobic interactions, to name some examples. In solution, the three-dimensional 
structure of a protein will adapt to the lowest energy conformation possible, even if that 
folded state is only slightly more stable than the unfolded state106,107,227. In the case of 
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amyloidogenic proteins, the amyloid fibril state is highly stable and low energy resulting 
in protein structures that are rich in hydrophobic β-sheet structures. These structures 
interact with each other in solution and aggregate. This aggregation develops from single 
monomers to oligomer and fibrillar species through nucleation driven events (Fig. 
16)22,228.  
 
 
Fig. 16: Simplified amyloid fibril formation process.  
 
Protein misfolding, aggregation and amyloid formation can be a highly varied process. 
Although it is protein dependent, acidic conditions have traditionally been the simplest 
method to generate fibrils of amyloidogenic proteins28,29; however, the process readily 
occurs under physiological conditions as well29.  
3.4 Monitoring amyloid fibril formation by Thioflavin T fluorescence spectroscopy 
Due to the high β-sheet content of amyloid fibrils, their formation can be 
spectroscopically monitored through the use of a specific amyloid binding dyes (such as 
Congo red or Thioflavin T (ThT)). The ThT dye is widely used to identify and quantify 
the formation of amyloid fibrils in vitro229,230. By itself, ThT has very little fluorescence 
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with an excitation (417 nm) and emission (480 nm) maxima231. However, when ThT 
binds to β-sheet rich domains of amyloid fibrils (Fig. 17), such as Aβ fibrils, its excitation 
(440 nm) and an emission maxima (490 nm) shift and the fluorescence intensity is 
significantly increased231.  
 
Fig. 17: (A) ThT and its interaction (B) with the β-sheet rich domains of amyloid fibrils.  
(C) Fluorescence shift for ThT binding to Aβ fibril species (seven-day incubation) vs. 
monomeric (zero days incubation) protein. 
 
If the protein aggregates analyzed do not consist of mostly β-sheet rich structures (e.g. 
amorphous deposits), the ThT will not bind and fibril formation will not be identified232. 
The ThT assay provides a valuable tool in quantifying the formation of amyloid fibrils 
from native protein monomers; however, just as with all research, additional evidence of 
fibril formation needs to be collected by using electron microscopy (EM) or atomic force 
microscopy (AFM) for example229. During tests of fibrillogenesis inhibitors, control sets 
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without the protein species should be run to determine if the compounds alone may 
fluoresce under the conditions of the ThT assay. At the same time, when this assay is 
used for assessing the fibril inhibition or disassembly, the compounds examined, such as 
curcumin and resveratrol, may displace the ThT from the binding sites233,234. The 
displacement of the ThT on the β-sheet rich structures results in decreased fluorescence 
signal, which suggests less amyloid fibril formation than what is present. Therefore, the 
ThT assay should be coupled with other methods confirming the formation of amyloid 
fibrils, such as EM or AFM. 
3.5 Atomic force microscopy of amyloid fibril formations 
Atomic force microscopy produces detailed 3D high-resolution images of biochemical 
samples, such as proteins and cells235. By utilizing the natural attractive and repulsive 
forces of the sample, a probe can be run across the surface in question to generate an 
image of it. There are three modes of operation for scanning the surfaces of different 
samples: non-contact, contact and tapping modes236. Contact mode is the most commonly 
used method for AFM scanning of the surface of a sample237. The strong repulsive forces 
give excellent resolution; however, these forces can damage delicate biological 
samples235. Non-contact mode measures the van der Waals forces between the tip and 
sample while maintaining the integrity of the sample; this technique is of low 
resolution235. The tapping mode, which combines the functionality of the contact and 
non-contact modes, provides the best features of contact and non-contact modes235 for 
biological samples. This allows the probe to only briefly come into close contact with the 
sample in order to provide a detailed picture without disrupting the surface of the sample. 
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AFM has been widely used to investigate the fibril formation of amyloidogenic 
proteins237.  
3.6 Synthesis of a library of small molecules 
 
The small molecules 1 – 16, 31 – 45 and 78 – 93 tested in this work were synthesized in 
Bela Török’s lab. The general synthesis of the compounds is provided in their respective 
chapters. 
The small molecules 17 – 30 were provided by the group of Donald Sikazwe at the 
University of the Incarnate Word, San Antonio, Texas. The general synthesis of these 
compounds is provided in chapter 9. 
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CHAPTER 4 
MATERIALS AND EXPERIMENTAL METHODS 
 
4.1 Chemicals and enzymes 
The phenol and aniline derivatives, ACh, BuCh, DMSO, DPPH, AAPH, ABTS, DTNB, 
fluorescein, Trolox, resveratrol, galantamine, ThT, ethanol, acetonitrile, TritonX-100, 
HEPES, potassium persulfate, monobasic sodium phosphate, dibasic sodium phosphate, 
NaCl, AChE from Electrophorus electricus/electric eel (catalog number: C2888-500UN), 
BuChE from equine serum (catalog number: C4290-1KU) and human insulin (catalog 
number: 11061-68-0) were all purchased from Sigma Aldrich.  Lysozyme from chicken 
egg white (210083405), muscovite mica V-2 (50–949-111), 1/8” diameter Teflon beads 
(1298222) and ascorbic acid were all purchased from Thermo Fisher Scientific. Magnetic 
discs (20 mm specimen metal discs for AFM 75010-20) were purchased from Electron 
Microscopy Sciences. The AFM tips (standard tapping mode AFM Probe PPNCHR-10) 
were purchased from NanoAndMore USA. Aβ was purchased from Anaspec. HCl was 
purchased from EMD chemicals. 
4.2 Amyloid fibril inhibition and disassembly procedures 
4.2.1 Lysozyme amyloid fibril formation 
Fibril preparation in 80% ethanol 
Hen egg white lysozyme (HEWL) protein (3.0 mg) with a molecular weight of 14,307 
g/mol was dissolved in 200 µL deionized water and stirred with a small magnetic stir bar 
for 10 min in a glass screw-cap vial. Then 800 µL 100% ethanol was added. The 80% 
ethanol HEWL sample was left with constant agitation for 2 weeks at room temperature 
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to form amyloid fibrils. The 80% ethanol lysozyme fibril sample was diluted with 
deionized water at 1:50 ratio to prepare the AFM sample. 
Preparation of heat denatured lysozyme aggregates 
For the preparation of heat denatured aggregates, 3.0 mg of HEWL (14,307 g/mol) 
protein was dissolved in 1.0 mL deionized water and stirred with a small magnetic stir 
bar for 10 min in an Eppendorf tube. The sample was then placed into a boiling (100 ºC) 
water bath for 15 min and then cooled to room temperature and used without further 
dilution. 
4.2.2 Insulin amyloid fibril formation  
Physiological buffer 
For the preparation of the buffer, NaCl (0.137 mol), KCl (0.0027 mol), Na2HPO4 (0.0081 
mol) and KH2PO4 (0.00147 mol) were dissolved in 900 mL of de-ionized (DI) water. The 
pH was adjusted to 7.5 with phosphoric acid and sodium hydroxide. The final solution 
was then diluted to 1 L with DI water and stored at 4 °C until use238.  
Acetic acid solution  
For the preparation of the acetic acid solution, NaCl (0.100 mol) was dissolved in 800 
mL of DI water. 200 mL of acetic acid was added and the solution was stored at 4 °C 
until use239. 
Insulin stock solution 
Insulin (14.2 mg) was dissolved in 350 µL of 1.0 M HCl. 
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Amyloid fibril formation of insulin under physiological pH conditions 
The stock solution of insulin (50 µL) was neutralized with 50 µL of 1.0 M NaOH in a 
screw cap microcentrifuge tube. The solution was diluted with 900 µL of PBS and was 
vortexed to ensure mixing. A 1/8” diameter Teflon bead was added to the 
microcentrifuge tube as a nucleation initiation to help the insulin fibril formation begin. 
The sample was incubated at 37 °C and shaken at 700 rpm. Samples were analyzed after 
2 days for amyloid fibril formation.  
Acidic conditions 70 °C 
The stock solution of insulin (5 µL) was diluted with 95 µL of acetic acid solution and 
the mixture was vortexed to ensure mixing. The sample was incubated at 70 °C. Samples 
were analyzed after two days for amyloid fibril formation.  
4.2.3 Thioflavin T binding assay 
Thioflavin T solution was freshly prepared by dissolving 1.0 mg ThT in 63.75 mL of 10 
mM phosphate buffer solution at pH 7.4 and 3 µL of the lysozyme solution were diluted 
with 960 µL of ThT solution. Background solutions with the samples were made 
replacing the ThT solution with the 10 mM phosphate buffer pH 7.4 solution. The 
fluorescence intensity of all samples was recorded with a Hitachi F-2500 fluorescence 
spectrophotometer and the FL Solutions 2.0 software at the excitation and emission 
wavelengths of 460 nm and 480 nm respectively.   
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4.2.4 Atomic force microscopy 
Sample preparation 
A magnetic disc sample holder was used for mounting the mica on the AFM stage. The 
mica was cut into a small square disc using double-sided tape. The top layer of mica was 
peeled off in order to have a surface free of imperfections. 2 µl of the diluted HEWL 
amyloid solution was placed on the center of the mica. After 2 min, to allow for 
adsorption onto the surface of the mica, the sample was rinsed with DI water, removing 
any unbound protein from the sample. The samples were left to air dry.  
Atomic force microscopy image collection 
The AFM images of the samples were taken with using a Bruker Innova Atomic Force 
Microscope in tapping mode with these parameters: resolution: 256 * 256 pixels (for 
quick scans) or 512 * 512 pixels (high resolution images), scan range: 200 nm to 100 µm, 
scan rate: between 0.3 to 1 kHz (adjustable for each sample). Analysis of AFM images 
was conducted with Image J software240,241. 
4.3 Ellman’s method for enzyme inhibition  
HEPES buffer (20 mM) pH 8.0 (0.1% tritonX-100) preparation 
For the preparation of the buffer, HEPES (0.9532 g) was added to 190 mL of DI water. 
The pH was adjusted to 8.0 with phosphoric acid and sodium hydroxide. The final 
solution was then diluted to 200 mL with DI water and 200 μL of TritonX-100 was 
added. The solution was stored at 4 °C until use. 
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Phosphate buffer (0.1 M) pH of 8.0 preparation (buffer A) 
For the preparation of the buffer, NaH2PO4 (0.0140 mol) and Na2HPO4 (0.0860 mol) 
were dissolved in 900 mL of DI water. The pH was adjusted to 8.0 with phosphoric acid 
and sodium hydroxide. The final solution was then diluted to 1 L with DI water and 
stored at 4 °C until use. 
 
Phosphate buffer (0.1 M) pH of 7.0 preparation (buffer B) 
For the preparation of the buffer, NaH2PO4 (0.0619 mol) and Na2HPO4 (0.0381 mol) 
were dissolved in 900 mL of DI water. The pH was adjusted to 7.0 with phosphoric acid 
and sodium hydroxide. The final solution was then diluted to 1 L with DI water and 
stored at 4 °C until use. 
4.3.1 Acetylcholinesterase inhibition assay preparation 
The AChE solution was prepared in aliquots of 6 U/mL (activity units/mL) in a 20 mM 
HEPES buffer at a pH of 8 (0.1% TritonX-100). The enzyme was stored at -20 °C and 
used when needed. Stock solutions of the inhibitors (experimental compounds and the 
controls galantamine and donepezil (Fig. 18)) were prepared at 10 mM in DMSO.  
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Fig.18: Control compounds for the AChE and BuChE inhibition. Experimental 
compounds were run at the IC50 of galantamine for each enzyme.  
 
Buffers A and B were incubated at 37 °C for 2 h. The inhibitor stocks were diluted to a 
0.15 mM solution through a co-solvent method using buffer A and acetonitrile (50% 
buffer A and 48.5% acetonitrile, with the remaining 1.5% being the DMSO solution of 
the compounds).  The DTNB dye was dissolved in buffer B to a concentration of 10.24 
mM and then further diluted with buffer A to 0.4331 mM. The inhibitors were added to a 
96 well plate to reach a concentration in the final assay of 2.0 μM. The DTNB solution 
was added to the 96 well plate into every well to a final assay concentration of 0.3410 
mM. The 96 well plate was incubated for 20 min. The AChE enzyme was diluted with 
buffer A (0.02 U/mL) and added to wells of the 96 well plate as seen in Fig. 19. 
Acetylthiocholine was dissolved in buffer A to a concentration of 4.124 mM and 20 μL 
was added to every well in the 96 well plate (Fig. 19). A Versamax microplate reader with 
SoftMax Pro software was used in kinetic mode at a wavelength of 412 nm at a 
temperature of 37 °C. Measurements were taken every 15 s for 15 min with shaking for 5 
s before every read.  
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Fig. 19: 96-well plate set up for AChE inhibition screening. 
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4.3.2 Butyrylcholinesterase inhibition assay preparation 
The BuChE enzyme was prepared in aliquots of 6 U/mL (activity units/mL) in a 20 mM 
HEPES buffer at a pH of 8 (0.1% Triton X-100). The enzyme was stored at -20 °C and 
used when needed. Stock solutions of the inhibitors (experimental compounds and 
galantamine) were prepared at 10 mM in DMSO. Buffers A and B were incubated at 37 
°C for 2 h. The inhibitor stocks were diluted to a 0.15 mM solution through a co-solvent 
method using buffer A and acetonitrile (50% buffer A and 48.5% acetonitrile with the 
remaining 1.5% being the DMSO solution of the compounds).  The DTNB dye was 
dissolved in buffer B to a concentration of 10.24 mM and then further diluted with buffer 
A to 0.4331 mM. The inhibitors were added to a 96 well plate to reach a final 
concentration of 10 μM. The DTNB solution was added to the 96 well plate into every 
well to a final assay concentration of 0.3410 mM. The 96 well plate was incubated for 20 
min. the BuChE enzyme was diluted with buffer A (0.02 U/mL) and added to wells of the 
96 well plate as seen in Fig. 20. Butyrylthiocholine was dissolved in buffer A to a 
concentration of 4.124 mM and 20 μL was added to every well in the 96 well plate (Fig. 
20). A Versamax microplate reader with SoftMax Pro software was used in kinetic mode at 
a wavelength of 412 nm at a temperature of 37 °C. Measurements were taken every 15 s 
for 15 min with shaking for 5 s before every read.  
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Fig. 20: 96-well plate set up for BuChE inhibition screening. 
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4.4 Free radical scavenging assays 
Preparation of 75mM phosphate and 50mM NaCl buffered solution with a pH 7.4 (PBS)  
For the preparation of the buffer, NaCl (0.05 mol), NaH2PO4 (0.0294 mol) and Na2HPO4 
(0.0456 mol) were dissolved in 900 mL of DI water. The pH was adjusted to 7.4 with 
phosphoric acid and sodium hydroxide. The final solution was then diluted to 1 L with DI 
water and stored at 4°C until use. 
Preparation of 75mM phosphate buffered solution with a pH 7.4  
For the preparation of the buffer, NaH2PO4 (0.0294 mol) and Na2HPO4 (0.0456 mol) 
were dissolved in 900 mL of DI water. The pH was adjusted to 7.4 with phosphoric acid 
and sodium hydroxide. The final solution was then diluted to 1 L with DI water and 
stored at 4 °C until use. 
Preparation of compound stock solutions 
Stock solutions of all experimental compounds were prepared at 50 mM in DMSO and 
known antioxidants Trolox (ethanol), resveratrol (ethanol) and ascorbic acid (water) were 
prepared at 10 mM. The stocks were further diluted to a working solution with ethanol 
for each of the antioxidant assays. 
4.4.1 DPPH radical scavenging assay  
The DPPH assay was carried out to assess the radical scavenging activity of a large group 
of compounds21,24,220,222. All compound and control stock solutions were diluted to 0.2 
mM with ethanol prior to evaluation. The 50% aqueous ethanol was incubated at 37 °C 
for 2 h and the DPPH was dissolved in 50% aqueous ethanol at a concentration of 105.3 
μM. It was further stirred for 1 h to ensure full dissolution. Water (100 μL) was added to 
the rows A and B as well as columns 1 and 12 of the 96 well plates to prevent solvent 
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evaporation during incubation. The control antioxidants and experimental compounds (5 
μL) were added to a 96 well plate, respectively, followed by 95 μL of the DPPH solution, 
or 50 % aqueous ethanol as can be seen in Fig. 21. The final concentrations of the 
compounds were 10 μM and the DPPH concentration was 100 μM. A Versamax plate 
reader set to 37 °C and 519 nm coupled with SoftMax Pro 5 software (Molecular 
Devices) recorded the absorbance of the wells every 15 min for 60 min with shaking for 5 
s before every reading.  
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Fig. 21: 96-well plate set up for DPPH radical scavenging activity screening. 
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4.4.2 ABTS radical scavenging assay  
The ABTS assay was carried out to provide more information on the total antioxidant 
capacity of the experimental compounds21,24,220,222. The ABTS radical solution was 
prepared by dissolving ABTS and K2S2O8 in water to a concentration of 7 and 2.45 mM 
respectively and stored in the dark at room temperature 16 h before performing the assay. 
The 75mM PBS pH 7.4 with 50 mM NaCl solution was incubated at 37 °C for 2 h. Every 
experimental compound and antioxidant standard was further diluted to 0.5 mM with 
ethanol. The concentrated ABTS solution was diluted with a 75 mM PBS pH 7.4 with 50 
mM NaCl solution to an absorbance reading of 0.7. Compounds and controls were plated 
in a 96 well plate at a final concentration of 10 μM (4 μL of diluted compound) and 196 
μL of the ABTS or buffer solution was added as seen in Fig. 22. Measurements were 
recorded using a Versamax plate reader set to 37 °C and 734 nm coupled with SoftMax 
Pro 5 software (Molecular Devices). Absorbance readings were recorded at the zero, six 
and twelve-minute time points.   
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Fig. 22: 96-well plate set up for ABTS radical scavenging activity screening. 
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4.4.3 ORAC radical scavenging assay  
To provide a further refined profile of the compounds as radical scavengers a third 
antioxidant assay, the ORAC assay, was conducted21,24,226. A fluorescein stock solution 
was prepared at a 4.19 μM concentration in a pH 7.4, 75 mM phosphate buffered 
solution. This fluorescein solution was diluted to 0.0816 μM solution fresh daily before 
performing the assay. The pH 7.4, 75 mM phosphate buffered solution and fluorescein 
working solution was incubated at 37 °C for 2 h.  The stock solutions of the compounds 
and known antioxidants were diluted to 80 μM in ethanol prior to screening the 
compounds. An AAPH solution was prepared in 4 °C pH 7.4, 75 mM phosphate buffer at 
a concentration of 153 mM prior to screening the compounds and stored on ice. A 25 μL 
solution of the compounds and control antioxidants were plated in a black 96 well plate 
and 150 μL of the working fluorescein solution was added to the wells of the 96 well 
plates (Fig. 23). The plate was incubated at 37 °C for 15 min after which, 25 μL of 
AAPH was added to the wells (Fig. 23). A SpectraMax i3x plate reader in kinetic mode 
set to 37 °C with excitation and emission wavelengths at 485 nm and 520 nm, 
respectively, was used to record the fluorescence of the wells every 2 min for 60 min.  
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Fig. 23: 96-well plate set up for ORAC radical scavenging activity screening.
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4.5 Calculation of physical descriptors of synthetic antioxidants and model 
compounds by Gaussian 09 for structure activity relationship studies 
The calculations were run in collaboration with Swarada Peerannawar in Bela Török’s 
lab. Frequency calculations for all compounds were performed to confirm the minima on 
potential energy surfaces. The effect of solvent (water) has also been studied for selected 
compounds to confirm their stability. The 1H NMR chemical shifts (δH) in DMSO for 
hydrazone and its azo tautomer were modeled by self-consistent reaction field (SCRF) 
calculations242 by incorporating the polarizable continuum model (PCM). The chemical 
shifts were calculated by subtracting the nuclear magnetic shielding tensors of protons in 
the hydrazone and its tautomer from those of the tetramethylsilane (reference) using the 
gauge-independent atomic orbital (GIAO) method243.  
The electronic structures of the phenol and aniline derivatives were determined using 
density functional theory (DFT) 244,245. Calculations were carried out at the B3LYP/6-
31G(d,p) level of theory using the Gaussian09 program suite246. The sum of the energies 
for the radical and the hydrogen atom in the starting compound were calculated. The N-H 
(and O-H for the compounds 62 - 78 and 90 - 93) bond dissociation energy (BDE) for the 
compounds was determined by subtracting the two energies. Additional parameters were 
also calculated to identify any experimental correlations between the compounds and 
their experimental antioxidant activities: N-H (as well as O-H bond distances for some 
compounds), dipole moments, logP values, HOMO and LUMO orbital energies, band 
gap energies, radical spin densities, proton affinities, ionization potentials. The 
experimentally derived Hammett constants, which were also used for assessment, were 
experimentally determined and obtained from the literature247. 
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CHAPTER 5 
β-CARBOLINES AS POTENTIAL MULTI-FUNCTIONAL ALZHEIMER’S DISEASE 
THERAPUTIC AGENTS 
 
5.1 Introduction 
The β-carboline core structure (Fig. 24) was extensively explored for drug development 
in diverse areas such as cancer therapy, anti-malarial agents, Alzheimer’s therapy, etc. 
 
Fig. 24: β-carboline core structure. 
 
Work on β-carboline alkaloids such as harmine (Fig. 25) has shown these compounds 
to be highly toxic to cancer cells248. The Chen lab further investigated 1-(4-hydroxy-3-
methoxyphenyl)-β-carboline-3carboxyl-Trp-Trp-AA-OBzl derivatives (Fig. 25) as anti-
cancer agents with approximately 50% tumor inhibition reported249. Novel 3,9-
substituted β-carboline derivatives (Fig. 25) were also investigated as anti-cancer 
agents showing promising results with several compounds having an IC50 of less than 
10 µM against several cancer lines250. The efficiency of β-carbolines as anti-malarial 
and anti-leishmanial agents have also been explored. They appeared to selectively 
target the parasites, having little to no cytotoxic effects on human cell lines144, 251, 252. 1-
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Benzyl-1,2,3,4-tetrahydro-β-carboline (Fig. 25) inhibits the N-methyl-D-aspartate 
(NMDA) receptors which are important for synaptic plasticity and memory function253. 
Inhibition of this receptor prevents the increase in intra cellular Ca2+ concentrations by 
blocking the voltage-dependent channel permeable to Ca2+ and Na+.253 Methyl-6,7-
dimethoxy-4-ethyl-β-carboline-3-carboxylate (DMCM) (Fig. 25) is used as a promoter 
of the GABAA  receptor254. Simple β-carbolines are also excellent antioxidants (Fig.25) 
255. 
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Fig. 25: Examples of β-carboline derivatives with different activities as drug 
candidates. 
 
 
The structural analysis of a large set of Aβ self-assembly inhibitors122,144 indicated the 
importance of extended aromatic structure as well as the presence of H-donor and H-
acceptor units in binding to the Aβ peptide. In addition, analyzing the structures of 
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cholinesterase inhibitors, it appears paramount to have a relatively extended structure 
that is able to span the active center of the cholinesterases involving a variety of 
hydrophobic units. The basic β-carboline skeleton fulfills these criteria. Thus, we have 
considered β-carboline derivatives as potential multi-functional AD agents. Based on 
earlier findings, the original three ring system has been extended with an additional 
aromatic ring either directly or via a carbonyl linker to test the role of molecular 
flexibility on the efficacy of anti-cholinesterase activity. The extended aromatic 
structures are also expected to contribute to the potential antioxidant activity. 
5.2 Synthesis 
The β-carboline derivatives were synthesized in the Bela Török lab at the University of 
Massachusetts Boston by the following general procedure by applying a 3-step-one pot 
domino reaction by using a special mixture of commercially available 5% Pd/C and K-10 
montmorillonite as a bifunctional catalyst (Scheme 1). The first condensation step 
between the aldehyde and tryptamine was catalyzed by the solid acid K-10. The imine 
formed immediately underwent a cyclization also by K-10 catalysis. The resulting 
tetrahydro-β-carbolines were dehydrogenated by the Pd metal to provide the aromatic β-
carbolines. Each product was characterized by 1H and 13C NMR spectroscopy and mass 
spectrometry (GC–MS). The spectroscopic characterization of the compounds was in 
agreement with their structures and the literature data256.  
 
Scheme 1. Synthesis of β-carboline derivatives. 
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5.3 Results 
Sixteen β-carboline derivatives were used in an effort to investigate the activity and 
potency of these compounds as potential multi-target drug candidates for Alzheimer’s 
disease. These included compounds with electron donating and withdrawing groups and 
hydrophobic substituents (Fig. 26), with more prominent aromatic units (Fig. 27) and 
compounds with having a carbonyl group as a linker between the β-carboline core and the 
additional aromatic unit (Fig. 28).  
 
Fig. 26: Compounds 1-9 are simple β-carbolines with an aromatic extension. 
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Fig. 27: Compounds 10 and 11 are β-carbolines with a more prominent aromatic 
extension to ideally provide increased compound surface for interaction in the active site 
of cholinesterases. 
 
 
Fig. 28: Compounds 12-16 are β-carboline derivatives where the aromatic extension has 
been linked via a carbonyl group. 
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The biochemical assays in this section (Aβ fibril and oligomer formation, AChE and 
BuChE, ABTS, DPPH and ORAC assays) outline the tests carried out on the β-carbolines 
to assess their potential as multi-target drug candidates. 
5.3.1 Inhibition of Aβ fibril formation 
As multi-target drug candidates, β-carbolines should be able to inhibit the formation of 
the toxic Aβ plaques that build up in the brains of Alzheimer’s patients. The data indicate 
that several compounds had a moderate inhibiting effect on the fibril formation of Aβ as 
tabulated in Table 2.  
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Table 2: Inhibition of Aβ fibril formation by β-carbolines 1-16. Negative inhibition data 
indicate that those compounds promoted the fibril formation compared to the inhibitor-
free control. 
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5.3.2 Inhibition of Aβ oligomer formation  
The activity of β-carbolines were also assessed as inhibitors of Aβ oligomer formation by 
the Harry Levine III group (University of Kentucky, Medical School) by the biotinyl-Aβ 
single-site streptavidin-based assay257. As the data in Table 3 show, the compounds were 
highly active in preventing the formation of soluble neurotoxic Aβ oligomers.  
 
Table 3: Inhibition of Aβ oligomer formation by β-carboline derivatives (1-16).  
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5.3.3 Inhibition of cholinesterase activity (AChE, BuChE) 
As described earlier, cholinesterases cleave ACh (or BuCh), an important 
neurotransmitter. Inhibition of these enzymes increases the amount of ACh in the 
synaptic cleft which leads to improved cognitive function. I have used the widely 
accepted Ellman’s method that follows the production of choline with the DTNB 
indicator to evaluate the kinetic activity of the enzyme (Chapter 4.3.2)217. Decreased 
reaction rate compared to the uninhibited control identifies compounds as inhibitors of 
the cholinesterase enzymes. The cholinesterase enzymes (AChE and BuChE) have 
different substrates (ACh and BuCh respectively) and inhibitors often show specificity, 
but some compounds may inhibit both AChE and BuChE (such as galantamine or 
donepezil). The activity of β-carbolines against AChE and BuChE was investigated at 
concentrations of 2 µM (AChE) and 10 µM (BuChE), respectively, as described in 
Chapter 3.1.  As shown in Table 4, the β-carbolines have negligible effect on the activity 
of AChE. In contrast, the compounds were highly active in the inhibition of BuChE. 
After the initial assays, IC50 values were determined using a dilution series from 4.0 nM 
to 10 µM.  
 
  
 73 
 
Table 4: Inhibition of AChE and BuChE by β-carbolines and IC50 for BuChE activity is 
shown below. The initial assays were carried out at 2 µM (AChE) and 10 µM (BuChE) 
concentrations of the tested β-carbolines. The values here represent the mean ± the 
standard deviation of the data (n = 2−6). 
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5.3.4 Free radical scavenging activity (ABTS, DPPH, ORAC) 
Since oxidative stress is a widely accepted contributor to AD progression, the ABTS, 
DPPH and ORAC21,220,224 (Chapter 3.2.1-3.2.3) assays were performed to investigate the 
radical scavenging activity of the compounds. The data collected in the radical 
scavenging assays suggested different modes of action by the investigated compounds, 
based on the differences in radical scavenging activity between the different assays. 
Several compounds showed comparable low activity in both the ABTS and DPPH assays 
(Table 5). The β-carbolines were most active against the relatively small peroxyl radical 
used in the ORAC assay and several surpassed the activity of the controls. Since peroxyl 
radicals are a common form of ROS, this observation is encouraging. 
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Table 5: Free radical scavenging activity of the β-carboline derivatives against the 
DPPHa, ABTSb and peroxyl radicalsc. The values here represent the mean ± the standard 
deviation of the data (n = 2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
 76 
 
 
5.4 Discussion 
The larger structures (2, 4, 6, 10, 12 and 14) acted as moderately active Aβ fibril 
formation inhibitors with the best performances shown by 2 (39%) and 10 (40%), which 
represents an approximately 110 µM EC50 value. 
A majority of the compounds produced more than 50% oligomer formation inhibition (1, 
6, 7, 9, 10, 15 and 16). The activity comparison of the compounds in the Aβ fibril and 
oligomer formation inhibition assays are in agreement with previous findings; namely 
that a compound is either a fibril or an oligomer formation inhibitor257,258. This is shown 
by the respective behaviors of 1, 15 and 16 that have Aβ fibril inhibition values of -4, -5 
and 6 while having Aβ oligomer inhibition values of 79, 84 and 82. However, compounds 
6 and 10 appear to provide a reasonable protection against the formation of oligomeric 
and fibrilized states of Aβ self-assemblies with Aβ fibril inhibition values of 34 and 39 as 
well as Aβ oligomer inhibition values of 82 and 58. 
Electrospray-ionization mass spectrometry data revealed convincing evidence that 10, 
which can block both fibril (39%) and oligomer (58%) formation of Aβ, forms a complex 
with the peptide in the solution (Fig. 29). The most typical complex appears to be the 1:1 
ratio of Aβ:10, although another complex with higher ratio (1:2) can be observed. The 
spectrum, however, shows that Aβ is still overwhelmingly in an un-complexed form, 
indicating that a limited amount of inhibitor could modify the self-assembly process by 
partially complexing/blocking the peptide. 
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Fig. 29: Electrospray ionization (ESI) mass spectrum of the Aβ1-40-peptide-10 mixture 
(30 µM to 150 µM). The relevant signals indicate 1:1 Aβ1-40 5+(947.4472  m/z) and 1:2 
Aβ1-40 4+(1238.0727  m/z) complex formations between the peptide and inhibitor 
compound. The intervals highlight the relevant peaks of the charged Aβ carrying 4 to 6 
positive charges.  
 
As shown in Table 4 the β-carbolines have negligible effect on the activity of AChE. In 
contrast, the compounds were highly active in the inhibition of BuChE; over 60% of the 
studied compounds appear to be a better inhibitor of BuChE than the control, 
galantamine. Several of them (e.g. 3, 10) show above 80% inhibition of the enzyme at 10 
µM concentration (the IC50 of galantamine). 
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To compare the potency of the compounds to others in the literature the IC50 values of 
compounds that showed >50% inhibition at 10 µM concentration were determined. The 
following IC50 values were obtained: 2–4.27 ± 1.30 µM, 3–3.06 ± 1.27 µM, 7–4.48 ± 
0.27 µM, 10–225 ± 30 nM, 14–1.29 ± 0.25 µM, 16–1.42 ± 0.73 µM. The data show that, 
as expected, these compounds in fact possess a better IC50 than the reference compound. 
Compound 10 was found to be the best inhibitor of BuChE; its 225 nM IC50 value is of 
practical importance for further lead development. While at this level of the research it is 
difficult to make structure activity relationship predictions it appears that the presence of 
an electron-donating substituents (CH3, OCH3) on the β-carboline ring positively affects 
the BuChE inhibition. In addition, considering the lower, additional ring, the bulkier the 
group, the better the effect. Compound 10 with the quite large naphthyl group was found 
to be by far the most effective inhibitor. 
With the aim of understanding the BuChE inhibition property of these molecules, two 
among the best compounds (10 and 16) were docked in the active site of BuChE (PDB 
code: 1P0I42) using the Glide module of the Schrodinger package259. The 
superimposition of compound 10 and 16 with donepezil and galantamine (known BuChE 
inhibitors) in the active site of the enzyme is shown in Figs. 30 and 31. 
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Fig. 30: Superimposition of compound 10 (blue) with donepezil (red) and galantamine 
(dark green) in the active site of huBuChE (PDB ID: 1P0I). (hydrogens are concealed for 
clarity). 
 
 
 
Fig. 31: Superimposition of molecule 16 (blue) with donepezil (red) and galantamine 
(dark green) in the active site of huBuChE (PDB ID: 1P0I). (hydrogens are concealed for 
clarity). 
 
The analysis of the docked structures revealed that while 16 is extended through the 
active site of BuChE the reference compounds galantamine and donepezil appear to bind 
in the right side of the active site in 1P0I (Figs. 30 and 31). The N-H at position nine of 
16 shows a hydrogen bonding interaction with the Pro285 and Thr120 residues, 
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respectively. In addition to that, the methoxy oxygen of 16 interacts with the Glu197 
residue of the active site. In contrast, compound 10 appears to bind to the enzyme very 
similarly to donepezil, which is one of the best-known inhibitors of AChE as well as 
BuChE. The binding of 10 stretched through the active site explains the IC50 that is an 
order of magnitude lower than that of 16. The N-H at position nine of 10 shows hydrogen 
bonding interaction with the hydroxyl group of Ser198. In addition to that two π- π 
stacking interactions were observed, first between the phenyl ring of indole and residue 
Trp231 and the second one between the naphthalene ring of compound 10 and residue 
His438. Likewise, a cation- π interaction was noticed between quaternary nitrogen of 10 
and residue Trp231.  
 
Since the compounds appear to act as selective BuChE inhibitors, a docking study was 
carried out with 15 and AChE to observe whether the compound-enzyme interaction 
would reveal the reasons for the negligible effect. Fig. 32 shows that the orientation of 15 
is significantly different from that of donepezil and galantamine. The molecule stretches 
completely through the active site while galantamine only occupies the right side of the 
pocket and donepezil also appears on the right side and turns back to the center. Although 
15 shows hydrogen bonding interaction with residues Phe295, Tyr124 as well as π - π 
interaction with Trp286, The338 and Tyr337 residues, it is likely, that several of these 
interactions do not block residues that possess a role in the catalytic action. 
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Fig. 32: Superimposition of molecule 15 (purple) with donepezil (red) and galantamine 
(dark green) in the active site of huAChE (PDB ID-4EY7) (hydrogens are concealed for 
clarity). 
 
 
It was observed that, ABTS radical scavenging activity was low for the β-carbolines with 
a range of 2% to 21% radical scavenging; comparatively low to the reference compounds. 
Similar tendency was observed from the DPPH assays; the scavenging activity was 
mostly uniform, but low and several compounds resulted in increases in DPPH 
absorbance (Table 5). This could be for one of three reasons: the compound has 
background absorption at the wavelength checked, the compound regenerated some of 
the degraded DPPH in solution, or the molecular interactions of the compound with the 
radical developed a species that has a higher molar absorptivity at the wavelength 
screened. Compound blanks with no DPPH were screened at the assay wavelength to rule 
out the background absorption of the molecules. While the results from the ABTS and 
DPPH assays did not reveal high activity, the scavenging data from the ORAC assay 
provided a different picture of the β-carbolines. In this assay most of the β-carbolines 
performed the same or better than the control antioxidants, with radical scavenging 
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percentages from 0% to 58% (Table 5). The large differences in the activity of the 
compounds between the three assays can provide some insight into the activity of the β-
carbolines. ORAC has historically been known to provide higher values to compounds 
that scavenge radicals at a slower rate (with the assay not differentiating between rate and 
efficiency of radical scavenging due to the in vitro generation of peroxyl species) and 
thus show up as lower activity in radical scavenging assays with shorter timescales21. The 
fact that the β-carbolines perform significantly better in the ORAC assay than in the 
ABTS and DPPH assays suggests they may be slow acting antioxidants, due to their high 
activity in the ORAC assay, but poor activity in the ABTS and DPPH assays. While slow 
radical scavenging activity is not ideal in an environment with a high rate of ROS 
activity, in a cellular system slower acting radical scavengers could potentially boost the 
endogenous antioxidant systems allowing them to continue to maintain the redox 
homeostasis within the cell. 
With the promising results for β-carbolines as Aβ fibril and oligomer inhibitors as well as 
their selectivity for inhibiting butyrylcholinesterase coupled with the strong activity in 
scavenging peroxyl radicals, the β-carbolines appear to be excellent candidates for further 
multi-target drug development for Alzheimer’s disease.  
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CHAPTER 6 
COMPUTER AIDED DRUG DESIGN OF MULTI-FUNCTIONAL HYDRAZIDE AND 
NIPECOTIC ACID DERIVATIVES 
 
This section focuses on the development of cholinesterase inhibitors developed computer 
aided by computational modeling and docking studies. A library of 14 hydrazide and 
nipecotic acid derivatives were designed through molecular docking with AChE to mimic 
the electrostatic characteristics of donepezil, a potent AChE inhibitor. The results below 
are the culmination of these findings. 
6.1 Introduction 
Computer aided drug design is a growing field in the pharmaceutical industry260. Aided 
by the increase in expression and identification of new protein species coupled with 
crystallography techniques, computational modeling of compounds at the active sites of 
enzymes has become a booming industry19. Computational modeling coupled with high-
throughput screening has allowed the compounds identified in the modeling studies to be 
efficiently investigated for activity260. Hydrazide–hydrazone derivatives have been 
investigated as standalone and hybrid drug candidates for a wide variety of ailments. For 
example, (2-Oxobenzoxazoline-3-yl) acetohydrazide261 derivatives (Fig. 33) are used 
clinically as anticonvulsants and many antibacterial agents currently in use contain a 
hydrazide–hydrazone moiety262. Imidazo[1,2-a]pyrazine-2-carboxylic acid arylidene-
hydrazides (Fig. 33) have also been investigated as potential anti-fungal agents263. 
Hydrazones have also been identified as potential antioxidants (Fig. 33)264.  
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Fig. 33: Examples of hydrazone and hydrazide derivatives with different activities as 
drug candidates. 
 
Nipecotic acid derivatives have also been investigated as drug candidates. Acting as an 
anticonvulsant, nipecotic acid (Fig. 34) inhibits GABA uptake in neuronal and glial 
cells265. New prodrug derivatives of nipecotic acid (Fig. 34) have been used as 
anticonvulsants266. Nipecotic acid derivatives with 4-substitution (Fig. 34) have been 
investigated as inhibitors of the GABA transporter mGAT1, which controls the 
glycosylation of proteins in the Golgi of developing sperm, to increase the overall sperm 
production267.  
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Fig. 34: Examples of nipecotic acid and derivatives with different activities as drug 
candidate anticonvulsants. 
 
The compounds 4,5-dimethoxy-2-nitrobenzohydrazide or hydrazones and 1-(1-
benzylpiperidin-4-yl)ethan-1-one or nipecotic acid derivatives were investigated due to 
their abilities to donate or accept hydrogen268. They can be readily derivatized with 
diverse hetero-/non-hetero aromatic groups to generate multi-functional drug 
candidates269,270. The molecules were designed to contain at least two hetero-aryl 
moieties spaced by a 2 to 3 carbonylated atom linker to electrostatically mimic 
donepezil271-273. 
6.2 Synthesis 
Hydrazide synthesis was conducted by the Sikazwe lab (University of the Incarnate 
World, San Antonio, Texas) by the following general procedure. Hydrazide synthesis 
occurred in two steps (Scheme 2)269,270,274. Step one involved refluxing methyl 4,5-
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dimethoxy-2-nitrobenzoate and excess hydrazine monohydrate in absolute ethanol and 
afforded intermediate. In step two, this intermediate was condensed with a variety of 
aromatic aldehydes to form arylated hydrazones. 
 
Scheme 2. General synthesis of hydrazide derivatives. 
 
Exploratory arylated nipecotic acid derivatives 28 – 30 (Fig. 36) were prepared beginning 
with the trimethylamine-facilitated N-benzylation of isonipecotate ethyl ester in toluene 
(Scheme 3)275. Ester hydrolysis, under basic reflux, led to the carboxylic acid 
intermediate, which was promptly converted to the acyl chloride via the dropwise 
addition of SOCl2. Finally, acyl chloride treatment with appropriate amines, in step three 
(Scheme 3), afforded target products 28–30.   
 
Scheme 3. General synthesis of nipecotic acid derivatives. 
 
  
 87 
 
6.3 Results 
Several of the fourteen 4,5-dimethoxy-2-nitrobenzohydrazide or hydrazones (Fig. 35) and 
1-(1-benzylpiperidin-4-yl)ethan-1-one or nipecotic acid derivatives (Fig. 36) exhibited 
potent antioxidant properties and modest AChE / BuChE inhibition (Table 6).  
 
Fig. 35: Structures of the synthesized hydrazides 17 – 27. 
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Fig. 36: Structures of the synthesized nipecotic acid derivatives 28 – 30. 
 
6.3.1 Cholinesterase (AChE, BuChE) docking studies using AutoDock Tools 
Since I participated in this study as a collaborator, I was not involved in the development 
of the hydrazide compounds investigated here. The compounds investigated were derived 
from AChE docking studies and designed to mimic the electrostatic profile of donepezil, 
a well-known inhibitor of both AChE and BuChE. Compound structures were identified 
through docking studies done by the Sikazwe lab (University of the Incarnate World, San 
Antonio, Texas) with AChE (PDB ID: 1EVE)272, using AutoDock Tools (Version 1.5.6) 
software and the correct protonation state of each ligand was determined at pH 7.4 using 
MarvinSketch (Version 17.2.27 ChemAxon, Cambridge, MA, USA)276. 
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6.3.2 Inhibition of cholinesterase activity (AChE, BuChE) 
The activity of the hydrazone-hydrazide derivatives 17 – 30 against AChE and BuChE 
were carried out at concentration of 2 µM (AChE) and 10 µM (BuChE) respectively. 
Most analogs poorly inhibited the enzymes. The exception was the nipecotic acid 
derivatives 28 and 30, which showed modest inhibition of both AChE and BuChE. The 
data are tabulated in Table 6.  
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Table 6: Inhibition of AChE and BuChE activity by the hydrazide and nipecotic acid 
derivatives. Galantamine (Ga) and donepezil (Do) were used as control compounds for 
cholinesterase inhibition. The values here represent the mean ± the standard deviation of 
the data (n = 2−6). 
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6.3.3 Free radical scavenging activity (ABTS, DPPH, ORAC) 
The hydrazide and nipecotic acid derivatives were investigated as radical scavengers in 
an effort to elucidate their potential multi-functional characteristics. Their activity in the 
DPPH, ABTS and ORAC assays can be seen in Table 7.  
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Table 7: Free radical scavenging activity of the hydrazide derivatives against the DPPHa, 
ABTSb and peroxyl radicalsc. The values here represent the mean ± the standard 
deviation of the data (n = 2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
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Unlike the AChE and BuChE data, these compounds showed excellent activity in the 
ORAC assays, suggesting they are effective free radical scavengers.  
6.4 Discussion 
The hydrazone-hydrazide derivatives were designed to mimic the structural and 
electronic properties of donepezil in an effort to design new AD drugs with multi-target 
functionality. These derivatives were not potent inhibitors of AChE or BuChE as 
donepezil is. Compounds 28 and 30 were the most active cholinesterase inhibitors with 
activity from 10-20% which is far less than the activity of the controls galantamine (56% 
for AChE and 36% for BuChE) and donepezil (97% AChE and 57% BuChE). Despite the 
low enzyme inhibitory effect, the antioxidant activity of these derivatives was promising. 
The hydrazone-hydrazide derivatives were most active against the comparatively small 
peroxyl radical used in the ORAC assay and several compounds surpassed the activity of 
the controls. Compounds 17, 20, 22 and 23 all performed >10% in the DPPH assay. The 
compounds exhibited reasonable activity in the ABTS assay with 17 and 22 all with 
>30% radical scavenging activity, performing just as good or better than the reference 
compounds ascorbic acid and Trolox. In the ORAC assay the compounds screened had a 
much higher radical scavenging activity with values obtained higher than 50% for 
compounds 17, 20, 22 and 23. Compounds 17, 20 and 22 were by far the best radical 
scavengers of all three antioxidant assays. 
These compounds are clearly not multi-target drug candidates for AD treatment. 
However, they showed strong antioxidant activity and several of them provided some 
degree of inhibition against AChE and BuChE. Further refinement of the structures of 
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compounds 28 and 30 for cholinesterase inhibition could potentially lead to stronger 
inhibitors and ultimately better drug candidates. 
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CHAPTER 7 
STRUCTURE ACTIVITY RELATIONSHIP OF HYDRAZONES AS RADICAL 
SCAVENGERS 
 
Building upon our earlier efforts on potential multi-target inhibitors264, the hydrazone 
core structure that yielded several excellent inhibitors against Aβ fibril and oligomer 
formation was further investigated. It was decided to explore the effects on the radical 
scavenging activity of these compounds with emphasis on finding a structure-activity 
relationship (SAR). Structural and energetic features of a series of fifteen 
diarylhydrazone derivatives were calculated by density functional theory (DFT). The 
major goal was to identify key features that most likely contribute to their antioxidant 
effect. The following section describes the work performed to form a SAR study using 
the radical scavenging activity correlated with the characteristics of the compounds.  
7.1 Introduction 
Hydrazone derivatives have been applied in a multitude of medical applications. A 
number of acetylhydrazones277, oxamoylhydrazones277 and hydrazones278 have been 
investigated and used clinically as anticonvulsants (Fig. 37).  Several N-
acylarylhydrazone derivative Ca2+ chelators270 and 2-(2-formylfuryl)pyridylhydrazones279 
have shown promise as anti-inflammatory drugs (Fig. 37).  
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Fig. 37: Examples of biologically active hydrazones. 
 
Hydrazones have gained attention in the pharmaceutical field and are being included in 
hybrid drugs to create more potent therapeutics24-26. A good example of this is that 
current research being done to synthesize new antibacterial drugs with several research 
groups working on combining pharmacophore properties of other antimicrobial drugs 
with a hydrazone backbone.  Several benzimidazole derivatives containing a hydrazone 
moiety280 and hydrazone derivatives of benzofuran281 have been used as antibacterial 
agents (Fig. 38). Hydrazone derivatives of quinolone and their respective Cu2+ and Zn2+ 
complexes are used to treat tuberculosis282 (Fig. 38). Drugs derived from 4-methyl-1,2,3-
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thiadiazole-5-carboxaldehyde benzoyl hydrazone283 have been used as antiviral agents 
and 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone284 has been used to fight 
malaria. Not only do hydrazones have a wide range of biological activities, but they have 
also been identified as potential antioxidants (Fig. 38)264. Due to their outstanding activity 
and multifunctional capabilities, hydrazones are excellent candidates for multi-target drug 
development.  
 
Fig. 38: Additional examples of biologically active hydrazones. 
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7.2 Synthesis 
The hydrazone derivatives were synthesized in the Bela Török lab at the University of 
Massachusetts Boston by the following general procedure (Scheme 4). General synthesis 
of the hydrazones was carried out in a 25-mL Erlenmeyer flask; 1 mmol of benzaldehyde 
and 1 mmol of phenyl hydrazine were dissolved in 2 ml of dichloromethane. The reaction 
mixture was stirred for 10 min at room temperature, then it was cooled to −20 °C for 30 
min to crystallize the products. The crystalline product was filtered and air-dried for 12 h. 
The purity was verified using GC-MS and NMR. Impurities were removed by 
recrystallization or preparative TLC to yield at least 98 % purity product. 
 
Scheme 4: Synthesis of the applied hydrazone derivatives. 
 
7.3 Results 
Fifteen hydrazone derivatives were selected from the Török lab’s earlier work on 
hydrazones as multi-target candidates for AD treatment264 in an effort to investigate their 
free radical scavenging activity. Compounds 31 – 42 were selected from this earlier study 
while compounds 43 – 45 have not yet been investigated. The antioxidant data was 
coupled with structural data determined using density functional theory (DFT) 
calculations. The list of compounds included molecules with electron withdrawing 
groups (such as CF3), hydrophobic residues, cyclized hydrazone structures and extended 
hydrazone structures (Fig. 39 and 40).  
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Fig. 39: Compounds 31 - 42 are hydrazones derivatized that have halogen and other 
electron withdrawing substituents.  
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Fig. 40: Compound 43 is a hydrazone that has cyclized through reaction of the hydrazone 
center with one of the substituents. Compound 44 is a hydrazone prepared from 
benzophenone and compound 45 is a simple double diarylhydrazone molecule prepared 
from 1,4-phthalaldehyde. 
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7.3.1 Free radical scavenging activity (ABTS, DPPH, ORAC) 
In the experimental studies, ABTS, DPPH and ORAC21,220,224 (Chapter 3) assays were all 
performed to investigate the radical scavenging activity of the hydrazones. The activity 
profile of the compounds appeared different in the three assays. Several compounds (37, 
38, 40 and 42) showed comparable activity to the reference compounds ascorbic acid and 
Trolox in all three assays (Table 8).  
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Table 8: Free radical scavenging activity of the hydrazone derivatives 31 – 45 against the 
DPPHa, ABTSb and peroxyl radicalsc. The compounds were screened at 10 µM for all 
three assays. The values here represent the mean ± the standard deviation of the data (n = 
2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
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The data reveal that the compounds showed a broad range of activity in the DPPH assay. 
Compound 43 exhibited no effect; several compounds appear to possess higher activities 
than those of the reference compounds (37, 38, 45) and the rest of the compounds showed 
moderate effect, similar to resveratrol; however, their radical scavenging is still higher 
than that of ascorbic acid and Trolox. The data are somewhat similar in the ABTS assay; 
here, resveratrol is a very strong radical scavenger; however, according to the literature, 
this assay often reports false high radical scavenging for this compound due to several 
issues such as kinetic rates of phenol oxidation or the generation of secondary products21. 
It was observed that only compound 39 is better than resveratrol, while the rest of the 
compounds showed varying effect (from 10 to 50 %) yet; most are more effective than 
ascorbic acid and Trolox. The ORAC data diverges from the previous two sets. The 
hydrazones were most active against the smallest peroxyl radical used in the ORAC 
assay, surpassing the activity of the controls. Since the peroxyl radical in the ORAC 
assay is closest in nature to naturally occurring reactive oxygen species, this observation 
is encouraging. In this assay, the hydrazones appeared to be highly active and although 
their radical scavenging is still somewhat lower than those of resveratrol and Trolox, the 
activity values range from 50 to 88 % (except 43, which remained inactive in the latter 
two assays as well).  
As a first observation, one can say that the compounds exhibit a strong structure-activity 
relationship in the DPPH and ABTS assays, while the studied limited variations of the 
substituents of the hydrazone core structure affect the antioxidant activity only in a 
moderate extent in the ORAC assay. It is important to note that compound 43 possessing 
a structure with no N–H bond uniformly did not exhibit any measurable effect. 
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7.3.2 Physicochemical parameter determination using the Gaussian09 program suite 
In an effort to understand the relationship between the hydrazone structural motifs and 
antioxidant activity, a more detailed structure-activity relationship (SAR) study was 
conducted. The electronic structures of the hydrazones were determined using density 
functional theory (DFT). Calculations were carried out at the B3LYP/6-31G(d,p) level of 
theory using the Gaussian09 program suite. The DFT calculations were performed in gas 
phase, calculating 10 different parameters (O-H bond distances, dipole moments, logP 
values, HOMO and LUMO orbital energies, band gap energies, radical spin densities, 
proton affinities, ionization potentials and bond dissociation energies) to conduct the 
SAR study (Table 9).  
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Table 9: Theoretical parameters of the hydrazones investigated. Values were determined 
using Gaussian09. (a - Å, b - hartree, c - eV, d - kcal/mol). 
 
N-H 
distancea μ (D) LogP HOMO
b LUMOb Band gapc BDE
d PAd Ionization potentiald 
Ionization 
potentialc 
31 1.017 3.570 3.62 -0.19413 -0.05095 3.89 66.85 209.4 6.76 155.97 
32 1.017 3.402 4.44 -0.19775 -0.05814 3.79 67.25 210.4 6.85 158.06 
33 1.017 8.315 3.10 -0.21650 -0.08302 3.63 69.27 199.4 7.24 167.00 
34 1.016 4.658 4.44 -0.18963 -0.04327 3.98 66.29 214.8 6.44 148.58 
35 1.014 1.748 4.77 -0.20307 -0.05814 3.94 69.90 210.8 6.92 159.70 
36 1.015 2.054 5.24 -0.20854 -0.06511 3.90 70.19 207.3 7.08 163.47 
37 1.014 3.580 3.68 -0.19371 -0.04857 3.94 64.75 211.5 6.58 151.85 
38 1.014 3.053 3.68 -0.19202 -0.04656 3.95 64.02 212.5 6.54 150.90 
39 1.016 0.804 2.48 -0.18701 -0.04027 3.99 66.68 213.3 6.56 151.45 
40 1.016 5.728 4.75 -0.17504 -0.03387 3.84 98.6 218 6.07 140.13 
41 1.017 5.812 3.51 -0.21777 -0.09755 3.2 68.59 198 7.32 168.97 
42 1.014 3.891 4.77 -0.17452 -0.033 3.85 67.86 221.05 6.05 139.55 
43 N/A 5.449 4.08 -0.22997 -0.06666 4.44 87.4 193.84 7.65 176.43 
44 1.02 2.276 5.51 -0.19515 -0.03277 4.41 92.02 232.6 6.44 148.59 
45 1.017 0.197 4.37 -0.17781 -0.05797 3.26 89.86 218 5.99 138.16 
 
7.4 Discussion 
In regard to the contribution of the structural features, it is believed that the antioxidant 
activity of resveratrol is partially due to its phenolic OH groups as well as its conjugated 
structure. As the hydrazones possess a similar structure to resveratrol, the possible 
contribution of the NH group as well as the partial conjugation was considered. The 
extended conjugation is a common characteristic in many natural antioxidants, such as 
lycopene (tomato), β-carotene (carrot), or curcumin (turmeric)285. It is proposed that the 
partial conjugation is achieved by the rapid equilibrium of the two potential tautomers of 
the hydrazones286 as illustrated in Scheme 5.  
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Scheme 5: Tautomers and the potential delocalized form of diarylhydrazones. 
 
First, the potential tautomeric forms of benzylidene-phenyl hydrazine (Scheme 5) have 
been investigated to reveal the stable form of the molecule, which would be the candidate 
for further calculations. The optimized geometry, electronic energy and relative 
stabilization energy of the two tautomeric forms were calculated by Gaussian at the 
B3LYP/6-31G(d,p) level (Fig. 41).  
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Fig. 41: B3LYP/6-31G(d,p) optimized geometries of hydrazone Form I and azo Form II 
of benzylidene-phenyl hydrazine. Electronic energy (E) is given in hartrees. Relative 
stabilization energies (ΔERel), expressed in kcal/mol, are given in parenthesis. 
 
The calculated relative stabilization energy data of the two resonance forms show that 
Form I with the–C=N–NH–unit is more stable than Form II with the –CH2–N=N– unit by 
9.9 kcal/mol. This energy difference between the tautomers is significant. Calculations 
revealed that the activation energy barrier between the Form I and Form II is EA = 62.26 
kcal/mol, which is relatively high and supports the stabilization of hydrazone (Form I) 
over its azo tautomer (Form II). The structure of the transition state (Fig. 42 A) and the 
intrinsic reaction coordinate diagram (Fig. 42 B) are shown in Fig. 42. 
 
  
 
E = -611.883075  
Hydrazone  Form I ( ΔERel = 0.0 )  
E = -611.867196 
Azo Form  II (ΔERel = 9.9 kcal/mol) 
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(A)        (B) 
    
Fig. 42: The structure of the transition state of between the two diarylhydrazone 
tautomers (A) and the intrinsic reaction coordinate diagram for the tautomerization (B). 
 
Since the overall electron delocalization may also play a role in the antioxidant effect, the 
electrostatic potential map of the tautomers has also been determined (Fig. 43) in order to 
identify potential electron-rich or electron-deficient areas in the tautomers.  
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Fig. 43: Hydrazone Form I and azo Form II of benzylidene-phenyl hydrazine at isovalue 
0.0004. The blue region shows electron-poor areas and the red region shows electron-rich 
surfaces. 
 
The electron density distribution appears to be significantly different in the case of the 
two tautomeric forms. Form I has more even electron distribution on the aromatic rings 
and the vicinity of the N–H bond shows an electron-poor character. In contrast, Form II 
has an electron-rich area in the vicinity of the N=N bond due to the presence of the 
double bond as well as the lone pairs of the N atoms. As a result, however, both aromatic 
rings exhibit a partially electron-poor character. In order to investigate the tautomeric 
equilibrium both experimentally and theoretically, the 1H NMR spectrum of the 
benzylidene-phenyl hydrazine has been determined in DMSO-d6 and calculated for both 
tautomeric forms. The data are shown in Fig. 44.  
  
Hydrazone Form I Azo Form II 
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Fig. 44: Calculated 1H NMR chemical shifts of the hydrazone form I and azo form II of 
benzylidene-phenyl hydrazine in DMSO. 
 
The experimental spectrum is very similar to the calculated chemical shifts of the 
hydrazone form. The azo tautomer is only visible to a strongly limited extent; a small 
singlet appears at 5.750 ppm that could represent the CH2 protons of the azo form. 
Therefore, the comparison of the theoretical and experimental 1H NMR data suggests that 
while the presence of the azo form is supported by the experimental spectrum, the 
contribution of this form appears to be negligible (less than 1 %). Thus, while the 
tautomeric equilibrium may contribute to a partially delocalized electron distribution, it 
likely is not a significant species in the radical scavenging processes that are related to 
the traditional mechanisms220. Based on the above studies, the hydrazone form was 
selected for further investigations.  
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As these molecules contain a variety of substituents in altering positions, a 
conformational analysis was carried out to determine the lowest energy conformers that 
would be used to calculate the parameters of the compounds for the structure-activity 
relationship studies. The optimized geometries and electronic energies of selected 
conformers are shown in Table 10. The comparison of the electronic energies allowed the 
selection of the most stable conformers that were used to calculate the parameters of the 
compounds that we applied in the structure activity relationship studies. In several cases, 
the identification was a rather simple task when the symmetry of the compound strongly 
favored a particular conformer. An interesting observation was made, however, when 
compounds with an -OH substituent were investigated. The minimum energy structure of 
hydrazones 37 and 38 (Table 13, entries 37, 38, conformer 3) exposed an intramolecular 
hydrogen bonding interaction between the hydroxyl group and the sp2-hybrid nitrogen 
from the hydrazone. As the phenolic OH group also participates in radical scavenging 
activity, this hydrogen bond might affect its ability to perform that function. The 
calculations revealed a similar trend in conformational stability both in aqueous solution 
as well as in the gas phase, indicating that the interaction with the water molecules does 
not disrupt the hydrogen bonding. Finally, based on the data in Table 10, the lowest 
energy structures for each compound were selected for calculating the different 
parameters of the compounds to be used in the structure activity relationship studies.  
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Table 10: Electronic energy (E) are given in hartree while the relative stabilization 
energies (ΔERel) are in parenthesis in kcal/mol units. 
compound conformer 1 conformer 2 conformer 3 selected 
conformer 
 
31 
 
E=-1071.487170 
(ΔERel=0.005 ) 
 
E=-1071.487178 
(ΔERel=0.0) 
  
2 
 
32 
 
E=-948.914773 
   
1 
 
33 
 
E=-3387.496664 
(ΔERel=0.0) 
 
 
E=-3387.492026 
(ΔERel=2.910) 
  
1 
34 
 
E=-1177.893122 
(ΔERel=0.0) 
 
E=-1177.893017 
(ΔERel=0.060) 
 
E=-1177.892232 
(ΔERel=0.492) 
 
1 
35 
 
E=-3520.02675 (ΔERel=0.0) 
 
E=-3520.018558 
(ΔERel=5.140) 
  
 
1 
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36 
 
E=-1285.945827 
(ΔERel=0.0) 
 
E=-1285.937467 
(ΔERel=5.245) 
  
 
1 
37 
 
E=-1138.625669 
(ΔERel=6.113) 
 
E=-1138.620439 
(ΔERel=9.395) 
E=-1138.635412 
(ΔERel=0.0) 
 
 
3 
38 
 
E=-1138.624073 
(ΔERel=6.304) 
E=-1138.618971 
(ΔERel=9.506) 
E=-1138.63412 
(ΔERel=0.0) 
 
3 
39 
 
E=-687.099116 (ΔERel=0.0) E=-687.098919 
(ΔERel=0.123) 
  
1 
40 
 
E=-1082.817095 
(ΔERel=0.0) 
E=-1082.816944 
(ΔERel=0.094) 
  
 
1 
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41 
 
E=-1153.412616 
(ΔERel=0.0) 
E=-1153.412329 
(ΔERel=0.180) 
  
 
1 
42 
 
E=-1082.817245 
(ΔERel=0.0) 
  E=-1082.807854 
(ΔERel=5.892) 
  
 
1 
43 
 
E=-1061.073094 
(ΔERel=0.1) 
 
E=-1061.073402 
(ΔERel=0.0) 
  
 
 
2 
44 
 
E=-882.140343 
   
 
 
1 
45 
 
E=-991.609857 
   
 
1 
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Several parameters such as N–H distance, dipole moment, logP value, HOMO-LUMO 
energies, band gap, bond dissociation energy, proton affinity and ionization potential of 
the above selected were calculated. The data are tabulated in Table 9.  
In order to uncover the potential contribution of the above calculated parameters to the 
radical scavenging activity, the relation of the parameters to the experimental data has 
been assessed. The analysis of the activity vs. property plots revealed that several 
parameters appear to influence the antioxidant activity (Figs. 45 and 46) while others 
seem to have no or only non-characteristic effects (not shown).  
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Fig. 45: Selected radical scavenging activity vs. BDE plots to illustrate the effect of the 
BDE on the activity of the hydrazones. Compound 43 was removed due to the cyclized 
structure and compounds with antioxidant activity higher than 80% (40, 44 and 45) were 
removed (see appendix - B). 
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Fig. 46: Selected radical scavenging activity vs. IP and logP plots to illustrate the effect 
of the parameters on the radical scavenging activity of the hydrazones.  
 
Foremost, the N–H bond dissociation energies (BDE) showed a correlation with the 
antioxidant activity. Based on the plots, obtained for the ORAC (R2=0.6505) and DPPH 
(R2=0.6081) assays (Fig. 45 A and B respectively), a linear relationship describes the 
effect of N–H BDE on the antioxidant activity, suggesting that decreasing BDE values 
result in increasing radical scavenging activity. The BDE effect is a clear indication that 
the hydrazones, at least partially, act via the hydrogen atom transfer (HAT) mechanism as 
described in Eq. 4.  
[Eq. 4] Ar-NH-N=CH-Ar + R. → Ar-N.-N=CH-Ar + R-H     
 
The HAT mechanism is the most common mechanism considered for the natural 
antioxidant polyphenols287. However, the poor correlation for the highest activity 
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compounds also indicates that while BDE is a strong contributing factor to the activity, it 
likely is not the only important characteristic.  
The underlying principle of the HAT mechanism is that low BDE indicates weak X–H 
bonds (X=N, O) which facilitate homolytic bond cleavage, thus providing H atoms to 
scavenge the target radical. Such a relationship is often observed for phenol derivatives, 
although the type of correlation varies288. It is important to note that compound 43, which 
does not possess an N–H bond, did not show any activity in either assay, a clear 
indication that the presence of the N–H bond is a necessary feature in these compounds. 
When comparing the calculated BDE with the experimentally observed antioxidant 
activity, it was found that compounds 37 - 39 and 42 show high experimental activities 
and have a low BDE. However, there are compounds, such as 40, 44 and 45, which have 
high BDE but also high activity in the assays and were removed from the plot due to poor 
sample size and correlation (see appendix- B). It must be noted that as the target radicals 
vary in the three assays, so does the correlation. Compounds 37 - 39 represent a specific 
group in which the compounds also possess a phenolic OH group in addition to the NH 
group of the hydrazone linkage. Similarly, in three-ring, hydrazone-like compounds, the 
phenolic OH group was claimed to be primary antioxidant, despite obtaining lower BDE 
values for the NH bond than for the OH bond289. Thus, to evaluate the reactivity of the 
NH–and OH groups in these compounds, BDE of the OH bond was calculated. The 
obtained BDE values for the –O–H bonds are 77.5 (37), 77.1 (38) and 73.8 (39) kcal/mol. 
These values are comparatively higher than those calculated for the N–H bond in the 
same compounds: 64.75 (7), 64.02 (38) and 66.18 (39) kcal/mol. In addition, several 
compounds (e.g., 32, 40, 42 and 44) that do not have phenolic OH substituent exhibit 
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similar or better antioxidant activities than those with it. Thus, our data provide further 
support to the earlier observations regarding the relative N–H vs O–H BDE values; 
however, in contrast to the earlier suggestion289, we found that the NH group is more 
efficient in the hydrogen atom transfer than the OH in these compounds. It is worth 
noting that just like molecules 37 -  39, compound 45 also contains multiple X–H bonds 
(two N–H) that may contribute positively to the antioxidant effect. The BDE of 45 
(89.85kcal/mol) is one of the highest in the studied groups despite that 45 exhibits one of 
the best activities. It is in line with the obtained exponential correlation. However, it also 
highlights that the number of active groups plays an important role. Another important 
feature appears to be the ionization potential (IP). A representative plot is shown in Fig. 
46 A for the ORAC assay; however, similar correlation was observed in the other assays 
as well. The data indicate a linear relationship (R2=0.5499) between IP and the 
antioxidant activity, namely, the activity decreases with increasing IP. This finding 
suggests that the radical scavenging by hydrazones is partially due to their participation 
in the single electron transfer (SET) mechanism290. This pathway occurs in three steps as 
shown in Eq. 5.  
[Eq. 5] Ar-NH-N=CH-Ar + R. → Ar-NH+.-N=CH-Ar +  R-     
               Ar-NH+.-N=CH-Ar  →  Ar-N.-N=CH-Ar + H+      
               R- + H+ → R-H          
 
According to the data and Eq. 5, the increasing IP value will decrease the extent of the 
formation of the Ar–NH+–N=CH–Ar radical cation and thus result in diminishing 
antioxidant activity. Compounds with low IP values, such as 40, 42, 44 and 45, either 
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having no additional substituents or the presence of electron withdrawing and electron 
donating substituents is balanced, have high activities. In contrast, the exclusive presence 
of electron withdrawing groups on both rings of the hydrazones in 33 (Br, NO2), 35 (Br, 
CF3), 36 (CF3, CF3) and 42 (NO2, CF3) decreases the possibility of electron transfer from 
the parent compound, hence decreases the antioxidant activity. In addition to the above-
discussed molecular features, the logP value that describes the partition of the compounds 
in aqueous and organic media is a common factor to consider in structure-activity 
relationship studies. As an example, the effect of logP on the antioxidant activity is 
shown in Fig. 46 B, which indicates that increasing lipophilicity (or logP) results in 
decreasing antioxidant effect (R2=0.7425). This effect can be explained by the assay 
conditions; all assays are carried out in hydrophilic medium, either in aqueous buffers or 
50 % aq. ethanol solution. Thus, compound 39 with a hydrophilic OH substituent showed 
the highest activity in the ABTS assay. However, when considering the logP factor, one 
must remember that for compounds to be considered as drug candidates, they must also 
possess a reasonable lipophilicity as well. The analysis of the other calculated 
characteristics did not reveal significant correlation with the antioxidant activity. 
The above results highlight clear and firm relationships between the structural and 
energetic features and their contribution to antioxidant activity for the studied group of 
hydrazones. However, it must be noted that an extended study with a broader group of 
hydrazones bearing more diverse substituents is needed to propose a quantitative 
description of the effect of these features that would make possible the rational design of 
antioxidants for potential therapeutic use. 
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CHAPTER 8 
EFFECT OF STRUCTURAL PARAMETERS OF PHENOL AND ANILINE MODEL 
COMPOUNDS ON THEIR RADICAL SCAVENGING ACTIVITY 
 
8.1 Introduction 
As mentioned earlier in Chapter 2, free radical damage has been identified as a common 
factor in the progression of many neurological diseases and radical scavenging could be 
incorporated into the design of multi-functional drug therapeutics. The most abundant 
plant-based antioxidants are polyphenols, which have a large structural variety291,292. A 
majority of the literature is primarily focused on the extraction, identification and 
quantification of their bioactivity57-61. Natural polyphenols may have excellent in vitro 
activity; however, their poor bioavailability limits their practical applications in 
biological systems57,73-77.  
 In the above experimental and DFT studies investigating the free radical scavenging 
activity of diarylhydrazones, it was established that the -NH group of the hydrazones 
provided significant free radical scavenging activity for these compounds245. Since there 
are several N-containing natural antioxidants (e.g. betalain, bilirubin or uric acid),64 it 
prompted us to evaluate the comparative activity of the -OH vs. the -NH groups. To 
avoid structural features that unnecessarily complicate the DFT studies (e.g. the 
possibility of conformational or E-Z isomers) we decided to focus on simple substituted 
phenols and anilines. 
The major aim of this work is to gain new insights to the fundamental mode of action of 
complex radical scavengers. Therefore, the experimental radical scavengin activity of 
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simple phenol and aniline model compounds was compared to investigate the effects of 
structural features. The selected compounds are simple, single ring structures that allow a 
direct comparison of the electronic and steric properties. While these molecules are not 
practical antioxidants, their simple structures offer a better opportunity to reveal 
important structural features that significantly affect their activity. In this work, our major 
goals were to (i) compare the antioxidant activity of similar phenol (-OH) and aniline (-
NH) derivatives and (ii) identify the effect of a broad variety of structural features (iii) to 
better understand the antioxidants’ mode of action.  
8.2 Results 
Thirty-two phenol and aniline model compounds were investigated through a SAR study 
to identify structural features resulting in increased radical scavenging activity. The 
compounds analyzed are commercially available and chosen to have a broad variety of 
substituents from the strongly electron withdrawing (EW) to electron donating (ED) 
groups and can be seen in Figs. 47, 48 and 49 
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Fig. 47:  The structures of phenol model compounds (46 - 62) investigated. 
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Fig. 48:  The structures of aniline model compounds (63 - 73) investigated. 
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Fig. 49:  The structures of phenol model compounds with an -NH group (74 - 77) 
investigated. 
 
Compounds 46 - 62 contain a phenolic -OH group while compounds 63 - 73 all contain a 
-NH2 group. Compound 74 is a hydroxyindole and is distinctly different than the other 
compounds in this study. Compounds 76 and 77 have both an -OH and -NH2 on the same 
phenyl ring. Compound 75 is tyrosine. The biochemical assays in this section (ABTS, 
DPPH and ORAC assays) were completed to identify compounds with radical 
scavenging activity. The experimental activity of these compounds was utilized in a SAR 
study to identify the structural parameters that are important for radical scavenging 
activity of phenol and aniline model compounds. 
8.2.1 Free radical scavenging activity of the model compounds (ABTS, DPPH, 
ORAC) 
Due to the high radical scavenging activity of polyphenols66-70 and the antioxidant 
activity of the hydrazones described in Chapter 7, this work was designed to investigate 
the activity of not just the substituted phenols, but also the effects of substituents on the 
activity of anilines as well. The experimental activities were determined using three 
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commonly applied and widely accepted assays; the DPPH, ABTS and ORAC protocols. 
Many of these compounds showed activity in all three of the radical scavenging assays 
(Tables 11 and 12).  
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Table 11: Free radical scavenging activity of the phenol model compounds 46 – 61 
against the DPPHa, ABTSb and peroxyl radicalsc. The values here represent the mean ± 
the standard deviation of the data (n = 2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
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Table 12: Free radical scavenging activity of the phenol and aniline model compounds 62 
- 77 against the DPPHa, ABTSb and peroxyl radicalsc. The values here represent the mean 
± the standard deviation of the data (n = 2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
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The three general mechanisms describing how antioxidants scavenge free radical 
species220,221: hydrogen atom transfer (HAT), sequential electron transfer (SET) and 
sequential proton loss electron transfer (SPLET) were reported in Fig. 10 in Chapter 3.2. 
The data reveals that although phenols have higher radical scavenging activity, anilines 
are also able to scavenge the investigated radicals. The data showed that almost every 
compound performed extremely well in the ORAC assay, with radical scavenging 
percentages almost always above 80% (Tables 11 and 12) except for compounds 70 and 
77 which had minimal activity in all three free radical scavenging assays. Compounds 
with high activity in the ORAC experiment are thought to primarily react through the 
HAT mechanism21. In contrast, the compounds exhibited uniformly negligible activity in 
the DPPH assay (Tables 11 and 12). Due to the uniform activity profiles that provided 
minimal variations, neither the DPPH nor the ORAC data were appropriate for the SAR 
analysis. In contrast, the radical scavenging of ABTS, which may occur through the SET 
and HAT mechanisms21, provided the most viable dataset for the compounds investigated 
(Tables 11 and 12). Thus, all further discussion will be based on the ABTS assay. It was 
observed that phenols generally performed better than anilines. Free radical scavenging 
assays, such as the ABTS assay, are known to report higher activities for compounds with 
multiple -OH groups220, which does not appear to be the case with our compounds (e.g. 
56, 57 and 59). While we noticed similar trends to those seen in the literature, it was 
found that the position of the -OH on the aromatic ring affects the activity of the 
compound more than the number of the -OH groups. 
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8.2.2 Determination of physicochemical parameters using the Gaussian09 program 
suite 
The electronic structures of the phenol and aniline derivatives were determined using 
density functional theory (DFT). Calculations were carried out at the B3LYP/6-31G(d,p), 
level of theory using the Gaussian09 program suite.   The sum of the energies for the 
radical and the hydrogen atom in the starting compound were calculated. The O-H and N-
H bond dissociation energy (BDE) for the thirty-two compounds was determined by 
subtracting the two energies. Additional parameters (Table 13) were also calculated to 
identify any experimental correlations between the phenols and anilines and their 
experimental radical scavenging activities: N-H and O-H bond distances, dipole 
moments, logP values, HOMO and LUMO orbital energies, band gap energies, radical 
spin densities, proton affinities, ionization potentials and the experimentally derived 
Hammett constants24
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Table 13: Theoretical parameters of the substituted phenols and anilines investigated. Values 
were determined using Gaussian09. (a - Å, b - hartree, c - eV, d - kcal/mol). 
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8.3 Discussion 
The ABTS data suggests a few key points. While the phenolic compounds have higher 
free radical scavenging activity, it is worth noting that compounds 66, 74 and 75 from the 
aniline set also have comparable activity to the best phenols. Additionally, benzoic acid 
compounds having -OH groups in different positions were also studied. If compounds 
possess higher activity solely by the number of -OH groups, compounds 52 - 60 should 
all have similarly high activity. Instead, varying activity was observed across these 
compounds with the highest activity belonging to benzoic acids with -OH groups located 
in the 1,3 positions. Another interesting trend with the ABTS data suggests that electron 
donating groups on the phenyl ring promote radical scavenging activity, e.g. compounds 
48 (Et) and 50 (Pr), respectively. The experimental data alone suggests that it is not just 
the amount of -OH groups present in the compound that correlate to activity, but there are 
other properties which significantly contribute to the activity of these phenol and aniline 
models. 
Correlating the theoretical properties of the compounds to the ABTS activity data led to 
several important observations. As these compounds have similar chemical structures, 
their experimental activity data and structural parameter values were expected to be 
related. Thus, the experimentally determined ABTS radical scavenging data have been 
plotted as a function of each calculated parameter set respectively. Then the obtained 
plots were analyzed in order to reveal potential relationships between the experimental 
activity and the characteristics. It was observed that several properties seem to have little 
to no effect on the activity of the compounds. -OH distance, -NH distance, logP, LUMO, 
spin density of O-radical, spin density of N-radical, proton affinity and Hammett 
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constants (meta) all appeared to be irrelevant as modulators to the radical scavenging 
activity (data not shown). Along with this observation, correlating the calculated 
properties with experimental activity using the complete compound set did not reveal any 
reasonable correlations with the data. (Data not shown) It suggests that comparing 
phenols and anilines in a single unified set is not a sufficient approach. Thus, it was 
decided to analyze the compounds in two separate groups as defined by their parent 
compounds, phenols and anilines. 
Phenols 
Phenols investigated in this set (46 - 62 and 74 - 77) showed several reasonable 
correlations between the ABTS radical scavenging data and the physicochemical 
properties examined. The HOMO energies are used to determine the likelihood of an 
electron to be donated by a compound79. Elevated HOMO values indicate that the 
compound is likely to donate electrons. The effect of the HOMO energies on the 
experimental activity of the phenols is depicted in Fig. 50. 
  
 134 
 
 
 
0
10
20
30
40
50
60
70
80
90
-0.24 -0.23 -0.22 -0.21 -0.2 -0.19
Ra
di
ca
l S
ca
ve
ng
in
g 
(%
)
HOMO (hartree)
(A)
y = 214296x2 + 97478x + 11103
R² = 0.902
0
10
20
30
40
50
60
70
80
90
-0.24 -0.23 -0.22 -0.21 -0.2 -0.19
Ra
di
ca
l S
ca
ve
ng
in
g 
(%
)
HOMO (hartree)
(B)
 135 
 
 
Fig. 50: (A) Effect of the HOMO energies of phenols on the radical scavenging activity 
of the compounds. (B) Activity vs. HOMO correlation for compounds 46 - 48, 51, 52, 54, 
55, 58, 59, 61 and 75 which correspond to the left parabola on (A). (C) Activity vs. 
HOMO correlation for compounds 49, 51, 56 - 58, 60, 74, 75 and 77 which correspond to 
the right parabola. 
 
Two activity wells can be identified in Fig. 50 A where the activity of the phenols drops 
between -0.20 and -0.21 hartree as well as between -0.22 and -0.23 hartree. These wells 
appear as two distinct but overlapping parabolic functions when all phenols are included. 
Compounds 46 - 48, 51, 52, 54, 55, 58, 59, 61 and 75 can be seen forming the left 
parabola (Fig. 50 B), while compounds 49, 51, 56 - 58, 60, 74, 75 and 77 form the right 
parabola (Fig. 50 C) The R2 values indicate a reasonable fit between the calculated 
functions and the data. Compounds 74 and 75 appear to be part of both functions. The 
compounds that form the left parabola (Fig. 50 B) are primarily consisted of single -OH 
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containing molecules, while compounds in the right parabola (Fig. 50 C) generally 
include molecules with multiple -OH groups.  
The LUMO energies for the phenols were found to be far too similar to identify a specific 
trend within the data set (Table 13). Similar to the above observations, the effect of the 
band gap energy on the activity yielded two distinct relationships (Fig. 51). 
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Fig. 51: Free radical scavenging activity vs band gap functions of (A) compounds 48 - 
53, 76 and 77 and (B) compounds 47, 56 - 58, 60, 61 and 74. 
 
Band gap energy is a common theoretical factor used to predict radical scavenging 
activity and to help determine stability of the spent antioxidant.  In Fig. 51 A, for 
compounds 48 - 53, 76 and 77 the activity vs. band gap energy relationship corresponds 
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to a linear function. The molecules that are plotted in Fig. 51 A are all compounds with a 
single -OH group. In contrast, compounds with multiple -OH substituents (47, 56 - 58, 
60, 61 and 74) plotted in Fig. 51 B, the activity vs. band gap energy function show an 
exponential relationship. Both functions can be characterized by reasonable R2 values, 
the linear relationships being an excellent fit (R2=0.964). Whether exponentially or 
linearly related, it seems clear that increasing band gap energy results in enhanced radical 
scavenging activity. When this band gap energy data is coupled with the HOMO energy 
correlations it suggests that phenols with high radical scavenging activity react primarily 
through the HAT mechanism where they donate a hydrogen atom to the radical species. 
The bond dissociation energy (BDE) is also a common feature to interpret the radical 
scavenging activity of an antioxidant293-295. This feature is often associated with the HAT 
mechanism; the stronger this bond, the less likely the antioxidant will react with the 
radical species in solution295. This is probably the best predictor of compounds that will 
react by the HAT mechanism, which involves the transfer of a hydrogen atom to the 
radical. The BDE calculations are usually restricted to X-H bonds, such as O-H and N-
H72. The activity vs. BDE data are depicted in Fig. 52. 
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Fig. 52: Effect of bond dissociation energy (BDE) of the phenols 46 - 48, 50 - 55, 74 and 
75 on their corresponding radical scavenging activity. 
 
Fig. 52 shows a less characteristic relationship as compared to Figs. 50 and 51. While the 
general trend indicates that BDE has an inverse relationship with the scavenging activity, 
the low R2 value suggests a relatively modest correlation. This could be due to 
experimental limitations; compounds with a greater number of -OH groups tend to be 
more reactive in these free radical scavenging assays than they would be in biologically 
relevant systems220. Removing all of the compounds with more than one -OH group (56 - 
63) as well as compounds 76 and 77 (dual -OH/NH) produces Fig. 52. The linear 
correlation of the BDE data with the ABTS scavenging activity of the single -OH 
compounds (46 - 48, 50 - 55, 74 and 75) shows that the lower the BDE of the –OH, the 
better free radical scavenger the compound will be. It indicates that the compound will 
likely donate a hydrogen atom that would terminate free radical species in solution. 
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Properties such as the LUMO and spin density of the O-radical did not show correlation 
with radical scavenging activity. However, where correlation between the properties and 
ABTS data exist, they are typically high (HOMO, band gap energy, BDE). All three of 
these properties suggest that the most important factor for phenols to be a free radical 
scavenger is the stability of the spent antioxidant. There is extensive literature available 
about polyphenols being potent free radical scavengers because they have more -OH 
groups present to scavenge the radical296,297. However, our investigations with the above 
model compounds suggest it is not necessarily the amount of -OH groups, rather the 
position of the -OH groups that is important. Fig. 53 highlights eight of our models with 
single and multiple hydroxyl groups along with the experimental ABTS scavenging 
activity. 
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Fig. 53: The structure and ABTS activity data of compounds 46, 49, 52 and 56 - 60. 
 
If the -OH content alone was responsible for the activity of the compounds, then 
compound 49 should have significantly lower activity then compound 46 and compound 
52 should have lower activity than compounds 56 - 60. This is not necessarily the case. 
Instead, the position of the phenolic -OH groups appears to be important in determining 
the activity. Hydroquinone (49) should be higher in activity than the phenol (46) and our 
study indicates this is not true, instead the single -OH phenol possess 1.4 times higher 
activity than hydroquinone. Several benzoic acids were also part of our analysis and the 
results led to the same conclusion. Most of the benzoic acids that have more than one 
phenolic -OH group (56, 57 and 59) have lower activity than 4-hydroxybenzoic acid (52). 
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However, compounds 58 and 60, where the -OH groups are in relative 1,3-positions 
respectively, have higher activity than compound 52. This suggests that the placement of 
the phenolic -OH groups is of primary importance; the 1,3 arrangement helps boost the 
radical scavenging activity. In fact, many of the potent polyphenols commonly 
investigated in the literature have this 1,3 – dihydroxy motif (resveratrol, cyanidin, 
catechin, quercetin, tannin, etc.)56,61,67.  
Anilines and other NH-containing compounds 
As the joint analysis of phenols and anilines did not result in coherent a SAR, it was 
decided to analyze the potential relationship between their calculated properties and 
experimental radical scavenging activity separately. Accordingly, we shift the discussion 
to primary amino group containing aromatics (anilines) and other –NH containing 
compounds. Consisting of compounds 63 – 73, 76 and 77, these models showed 
widespread correlations between the ABTS scavenging data and their properties. Anilines 
(67 - 72) had significant correlation between their ABTS scavenging data and dipole 
moment (Fig. 54). 
 
 143 
 
 
Fig. 54: Effect of dipole moment on the ABTS scavenging activity of anilines 67 - 72. 
 
The dipole moment of a potential radical scavenger may offer information on the 
potential stability of the spent antioxidant that is often another radical295. Anilines, unlike 
substituted phenols, showed a linear trend upon further refining the data (Fig. 54) by 
removing aniline (79) and a few of the compounds with groups that may sterically hinder 
the interaction of the -NH2 with the bulky radical species (64 - 66, 73, 76 and 77). A low 
dipole moment suggests more pronounced delocalization in the molecule that can 
contribute to the stabilization of the lone electron left on the spent antioxidant. Stability 
of the spent antioxidant is important to prevent the antioxidant from behaving like an 
active radical. 
Similar to the phenols it appears that the radical scavenging activity of anilines is also 
affected by their HOMO energy. In Fig. 55 compounds 63 - 73 and 77 can be seen 
forming an exponential relationship with activity. 
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Fig. 55: The effect of HOMO energies of the anilines (63 - 73 and 77) on their 
scavenging activity. 
 
Unlike the phenols, the activity of anilines grew with increasing HOMO energy, 
suggesting that the more likely the anilines were to share the electrons, the better the 
antioxidant they were, which would be expected for compounds reacting through the SET 
mechanism. Based on previously outlined mechanisms of free radical scavenging activity 
the ability for anilines to share electrons explains their activity in the ABTS assay. As it 
was the case with phenols, the LUMO energies for the anilines were also too similar to be 
able to identify a specific trend in the data (Table 13).  
An exponentially growing trend was identified in the band gap energy data for anilines 66 
- 68, 71 - 73, 76 and 77 (Fig. 56). Much like the band gap energy-activity relationship of 
the phenols stabilization of the spent antioxidant is very important298. 
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Fig. 56: Effect of band gap energy of the anilines on their radical scavenging activity with 
compounds 63 - 65 and 70 removed. 
 
The activity vs. BDE plot of the anilines also appears relevant and shows a correlation 
with the ABTS activity data (Fig. 57). The exponentially declining activity as a function 
of BDE is in agreement with expectations and with the well-established HAT – 
mechanism, in which a direct H-atom transfer from the antioxidant to the radical would 
ensure the radical scavenging effect. 
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Fig. 57: Radical scavenging of anilines as a function of their bond dissociation energy 
(BDE) with compounds 67 and 76 removed. 
 
Ionization potential (IP) is important for the evaluation of antioxidants, as the electron 
transfer from the scavengers to the radical species is an essential step in the SET 
mechanism296. Anilines show an inverse linear correlation between free radical 
scavenging activity and the ionization potential. The ionization potential (Fig. 58) of the 
compound decreases as their free radical scavenging activity increases. This is in direct 
agreement with the literature which suggests that the first step in SET mechanism (the 
donation of an electron from the antioxidant compound to the radical species) is 
favorable for these anilines295,298.  
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Fig. 58: Effect of ionization potential (IP) of the anilines on their experimental radical 
scavenging activity with the compounds 70 and 76 removed. 
 
Activity vs. proton affinity (PA) plots can be used to determine the likelihood of a 
compound scavenging the radical species through the SPLET mechanism286. Elevated 
proton affinity values suggest that the molecule may undergo heterolytic cleavage and 
release an H+ to solution (first step of SPLET mechanism)299. In Fig. 59 the data show 
that anilines have proton affinity values higher than 200 kcal/mol and as the proton 
affinity increases the free radical scavenging activity also increases. The data suggest that 
anilines do not operate solely under one mechanism rather, they interact with radicals 
through a variety of pathways, likely SET and SPLET.   
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Fig. 59: Effect of proton affinity (PA) of anilines on the ABTS radical scavenging 
activity with the compound 76 removed. 
 
Hammett constants (σ) were investigated to identify possible inductive or resonance 
effects on the free radical scavenging activity of the anilines247. Using compounds with a 
similar backbone that have varying substituents allows us to investigate the effects the 
substituents may have on the overall electron density of the compound and ultimately 
investigate the stability of the spent antioxidant286. The substituents in both the meta and 
para positions in the phenols are mostly other -OH groups, so the data collected for 
phenols does not provide much useful information. The data collected from anilines 
shows a more interesting trend. Fig. 60 exhibits a linear correlation between the para 
Hammett constants and the ABTS radical scavenging activity suggesting that electron 
donating substituents such as ethyl and propyl increase that free radical scavenging 
activity of the anilines. A trend does not develop with the meta Hammett constants. 
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Fig. 60: Radical scavenging of anilines as a function of their Hammett constants (para) 
with compound 76 removed. 
 
Electron withdrawing groups such as -CF3 and -NO2 have had a tremendous impact on 
the free radical scavenging activity of the anilines. The -NO2 containing compounds were 
removed from most data sets to provide a better estimate of the correlation of the ABTS 
activity with the theoretical properties of the molecule. Interestingly enough, the 2-
amino-4-nitrophenol still retained a 43% radical scavenging activity in the ABTS assay. 
This is most likely due to the presence of the -OH on the phenyl ring. Summarizing the 
above analysis, the factors that appeared to have meaningful effect on the ABTS radical 
scavenging activity are tabulated in Tables 14 and 15. 
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Table 14: Major properties of phenols that the show considerable fit with the 
experimental ABTS radical scavenging data. 
Parameter Function Fit 
(R2 value) 
Note 
HOMO 
energy 
y = 214296x2 + 97478x + 11103 0.902 mono-
phenols 
HOMO 
energy 
y = 154028x2 + 63636x + 6591.9 0.812 dihydroxy 
compounds 
Band gap  y = 59.255x -291.33 0.964 mono-
phenols 
Band gap  y = -29.274x2 – 330.45x – 852.15 0.861 dihydroxy 
compounds 
Bond 
dissociation 
energy 
(BDE) 
 
y = -9.5372x + 747.01 
 
0.737 
 
 
Table 15: Major properties of anilines that the show considerable fit with the 
experimental ABTS radical scavenging data. 
Parameter Function Fit 
(R2 value) 
Note 
Dipole 
moment 
y = -7.8149x + 44.873 0.935  
HOMO 
energy 
y = 26859x2 + 12248x + 1398.4 0.744  
Band gap  y = -317.9x2 – 3563.2x -9941.1 0.762  
Bond 
dissociation 
energy 
(BDE) 
 
y = 2E+18e-0.495x 
 
0.730 
 
Ionization 
potential 
(IP) 
 
y = 2.0908x + 370.42 
0.863  
Proton 
affinity (PA 
y = 0.0885x2 – 34.98x + 3458.4 0.696  
Hammett 
constants 
(σ) 
y = 33.709x + 29.261 0.626 para 
only 
 
 
It appears that while the phenols and anilines used do not form a unified model set that 
result in coherent picture, analyzing them separately yields valuable information. HOMO, 
band gap and bond dissociation energy data are of high importance to determine the 
radical scavenging activity of both groups. Interestingly, these are the only parameters 
that seem to contribute to the activity of phenols. During the analysis, it was found, that 
even monophenols and dihydroxy derivatives cannot/should not be handled together. 
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When evaluated separately, these two groups resulted in meaningful fits between the 
experimental data and calculated HOMO and band gap energies. Based on the data 
obtained phenols appear to act predominantly via HAT mechanism. The experimental 
radical scavenging data of aniline derivatives reveal strong free radical scavenging 
properties that are competitive with those of phenols. The theoretical analysis of their 
properties, however, indicates that while anilines also act via HAT mechanism, their 
mode of action is somewhat more complicated. Reasonable fits with ionization potential 
and proton affinity values suggest that these compounds at least partially scavenge 
radicals via the SET and SPLET mechanisms as well. This complex mode of action could 
contribute to the versatility of aniline-NH-containing natural and synthetic antioxidants 
and make them novel candidates in antioxidant-based therapeutic applications. 
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CHAPTER 9 
HYDRAZONES AS MULTI-FUNCTIONAL CK2 ENZYME INHIBITORS 
 
As described above (Chapter 7) among other effects, hydrazones have free radical 
scavenging activity and cholinesterase enzyme inhibition. The SAR relationship study 
(Chapter 7) was the phase 1 of our development of multi-functional CK2 enzyme 
inhibitors. Fluorinated hydrazone derivatives (phase 2) were designed and synthesized 
based on preliminary CK2 enzyme inhibition data obtained from the phase 1 compounds 
to further investigate the activity of hydrazones as a new class of CK2 inhibitors.  The 
following work aims to introduce this previously unexplored class of compounds as 
potential multi-functional inhibitors of CK2. At this time this work is still in progress and 
here I will focus on the relevant antioxidant data. 
9.1 Introduction 
Casein kinase II (CK2) is a ubiquitous serine/threonine kinase, which is known to 
influence cell survival, growth and death191-193. The expression of CK2 can suppress 
apoptosis leading to cell survival and is elevated in almost all types of cancer192,193,195. A 
defining factor of CK2 inhibitors is the presence of a hydroxyl, nitro, amino, or halogen 
substituents, which interact at the ATP binding site or through other possible modes of 
inhibition216. Examples of known inhibitors of CK2 can be seen in Figs. 6 and 7 in 
Chapter 2.  
To further improve the pharmokinetic properties of drug candidates they should also have 
features that allow for better absorption and distribution within the body. Addition of 
fluorine has been shown to enhance the ADME properties of drug candidates300,301. 
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Single fluorine incorporation or the replacement of a methyl group with a trifluoromethyl 
group is commonly used to improve metabolic stability, bioavailability and protein–
ligand interactions300,301. The introduction of fluorine to a molecule has been shown to 
decrease the pKa of a compound, due to fluorine’s electronegativity300,301. It also 
increases the bioavailability of the compounds in the body300,301. Aromatic fluorination 
has also been shown to increase the lipophilicity of drug candidates300,301. Fluorine-
carbon bonds are highly stable and improve the overall metabolic stability and resist 
oxidation by cytochrome P450 enzymes reducing the clearance rates of compounds in the 
body further increasing their distribution times300. As such there has been interest in 
adding or replacing parts of existing and developmental drug candidates with F atom or 
CF3 group301,302. Additionally, the inclusion of radioactive fluorine in compounds also 
allows for direct imaging of the compound’s distribution in the body through in vivo 
fluorine magnetic resonance301,303. This is essential for understanding the distribution, 
namely mapping where specific drug candidates are being delivered in the body. 
9.2 Synthesis 
The fluorinated hydrazone derivatives (phase 2) were synthesized in the Bela Török lab 
at the University of Massachusetts Boston by the following general procedure (Scheme 
6). General synthesis of the hydrazones was carried out in a 25-mL Erlenmeyer flask; 1 
mmol of benzaldehyde and 1 mmol of phenyl hydrazine were dissolved in 2 ml of 
dichloromethane. The reaction mixture was stirred for 10 min at room temperature, then 
it was cooled to −20 °C for 30 min to crystallize the products. The crystalline product 
was filtered and air-dried for 12 h. The purity was verified using GC-MS and NMR. 
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Impurities were removed by recrystallization or preparative TLC to yield at least 98 % 
purity product. 
 
Scheme 6. Synthesis of the fluorinated hydrazone derivatives. 
 
9.3 Results 
Sixteen hydrazone derivatives were developed based on CK2 enzyme inhibition findings 
from the phase 1 compounds (Chapter 7) conducted by the Baier lab at the John Paul II 
Catholic University, Lublin. Both phase 1 and phase 2 hydrazones can be seen in Figs. 61 
and 62. To assess their multi-functional capabilities phase 2 derivatives were screened for 
radical scavenging activity. Based on the experimental data from the phase 1 assays and 
feedback from the collaborator the design of extensively halogenated derivatives was 
carried out. Since C-Br, C-Cl bonds are easier to cleave and thus produce toxic 
byproducts we focused on organofluorine compounds. The extensive fluorination is 
believed to foster a better small molecule-enzyme interaction; hence stronger inhibition 
of the enzyme activity.  
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Fig. 61: Phase 1 compounds 31 - 42 are hydrazones identified with those from the SAR 
study on radical scavenging activity from Chapter 7. Phase 2 compounds 78 – 88 are 
heavily fluorinated hydrazones with varying substituents.   
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Fig. 62: Phase 1 compounds 43 – 45 are hydrazones identified with those from the SAR 
study on radical scavenging activity from Chapter 7. Phase 2 compounds 89 – 93 are 
double hydrazone derivatives which have been heavily fluorinated.  
 
9.3.1 Free radical scavenging activity (ABTS, DPPH, ORAC) 
From Chapter 7 the radical scavenging activity of the phase 1 hydrazones was already 
determined and described. It was observed that these hydrazones were most active 
against the smallest peroxyl type radical used in the ORAC assay surpassing the activity 
of the controls with activity values ranging from 50 to 88% for all compounds except 43, 
the cyclized hydrazone which lacks an N-H bond. Phase 2 hydrazone derivatives 78 - 93 
are heavily fluorinated, with the idea that the increased halogenation may provide better 
interaction of these compounds within the active site of the CK2 holoenzyme. The radical 
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scavenging feature of the compounds has been assessed by the DPPH, ABTS and ORAC 
assays. The data are tabulated in Table 16. Many compounds showed comparable or 
better activity to the reference compounds ascorbic acid and Trolox in all three assays. 
Unlike the phase 1 hydrazones the data for compounds 78 – 93 are not as uniform and 
may provide more insights into the radical scavenging activity of these hydrazones. 
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Table 16: Free radical scavenging activity of the phase 2 hydrazone derivatives against 
the DPPHa, ABTSb and peroxyl radicalsc. The values here represent the mean ± the 
standard deviation of the data (n = 2−6). 
 
a: Calculation for DPPH radical scavenging activity can be seen in Chapter 3.2.1. Eq. 1 b: Calculation for ABTS radical scavenging 
activity can be seen in Chapter 3.2.2. Eq. 1. c: Calculation for ORAC radical scavenging activity can be seen in Chapter 3.2.3. Eqs. 2 
and 3. 
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The phase 2 hydrazone derivatives 78 - 93 all had activity in the DPPH assay with 78, 79, 
90, 91 and 93 showing approximately the same radical scavenging activity as the three 
controls. The fluorinated hydrazones (78 – 93) all had radical scavenging activity, in the 
ABTS assay as well, higher than that of ascorbic acid and Trolox except for 92, with 
derivatives 86 – 88 all above 50%. In the ORAC assay, compounds 78 – 93, all exhibited 
radical scavenging activity greater than 10% with compounds 78 – 81 all at above 80% 
free radical scavenging and compounds 82, 83, 87 and 91 all having radical scavenging 
activity higher than 45%.  
9.3.2 CK2 enzyme inhibition 
The phase 1 hydrazones were investigated as CK2 holoenzyme inhibitors in an effort to 
determine their viability as potential multi-target therapeutic agents for the treatment of 
cancer. Currently, only the monomeric CK2α and CK2α’ subunits have been investigated 
for enzyme inhibition with hydrazones 31 – 45. From these enzyme studies IC50 values 
were determined for the active compounds. None of the investigated hydrazones had any 
inhibitory effect on the monomeric CK2α, however they exhibited inhibitory activity, 
with IC50 values from 1 to 15 µM, for compounds 31, 36, 37, 38, 40, 42 and 45 on 
monomeric CK2α’. This suggests that these hydrazones are selective inhibitors for the 
CK2α’ subunit. The link between effective halogenated inhibitors and CK2α’ inhibition 
led to the development of the fluorinated hydrazones in phase 2. Studies are still being 
conducted on the CK2α2β2 and CK2α'2β2 holoenzyme structures. The phase 1 hydrazone 
derivatives with CK2α’ inhibition also have moderate antioxidant activity in all three of 
the antioxidant assays, except for compound 36 which has an ABTS scavenging activity 
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of 8%. This suggests that hydrazones could be investigated as multi-functional 
candidates. 
9.4 Discussion 
Hydrazone derivatives were selected in an effort to develop multi-functional drug 
candidates for the inhibition of the CK2 holoenzyme. Based on my earlier work, 15 
hydrazone compounds (discussed in Chapter 7) was analyzed through a SAR study to 
correlate the physicochemical properties of the compounds to their radical scavenging 
activity. These derivatives 31 – 45, showed excellent activity in the ORAC assay with 
radical scavenging values ranging from 50 to 88% for all compounds except 43, a 
cyclized hydrazone. Most of the hydrazones in phase 1 showed moderate activity in the 
DPPH and ABTS assays with radical scavenging activity for most compounds lower than 
30% in both assays. The structure of phase 2 hydrazone derivatives were designed with 
one goal; to increase the amount of halogen substituents, mainly F, on the aryl rings. The 
reasoning for this is two-fold: halogenated hydrazones from phase 1 showed lower IC50 
values than others suggesting that halogenation is important for the hydrazone’s ability to 
inhibit CK2α’ and to improve the ADME properties301 of the compounds. While these 
compounds have yet to be assessed for CK2 inhibition, their radical scavenging activity 
was determined through the ABTS, DPPH and ORAC assays.  
The phase 2 hydrazones exhibited different radical scavenging profiles than their 
counterparts in phase 1. The ORAC scavenging activity had significantly decreased with 
only the 4-N, N dimethyl compounds (78 – 81) showing activity higher than 80%. At the 
same time, the ABTS and DPPH activity profiles of these compounds were also enhanced 
with most compounds showing higher than 30% activity in the ABTS assay (with the 
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exception of compounds 89 and 92) and higher than 25% in the DPPH assay (with the 
exception of compounds 84 and 87). The addition of the electron withdrawing fluorine 
groups has altered the radical scavenging activity of these compounds. We can see by 
looking at compounds 84 to 88 (which have fluorine substituents in every available 
position on at least one of the aromatic rings of the hydrazone) that in general the 
antioxidant activity decreases. However, compound 86 still seems to retain some activity, 
likely due to the 4-CF3 group present in the R2 position which also seems to provide 
activity to compounds 39, 42 and 91. This data suggests that hydrazones have potential as 
multi-functional therapeutics functioning as free radical scavengers, CK2α’ inhibitors and 
as potential AD therapeutic agents (discussed in Chapter 7). This work is still in progress 
and after the full profile of the hydrazones as CK2 inhibitors is completed more work still 
needs to be done. 
  
 162 
 
CHAPTER 10 
METHOD DEVELOPMENT OF AMYLOID FIBRIL FORMATION FOR 
EDUCATION AND RESEARCH 
 
10.1 Introduction 
Amyloidogenic structures have been identified in the misfolded states of many different 
proteins such as lysozyme, insulin, Aβ, α-synuclein and many others304. These structures 
are rich in tightly packed β-sheet formations held together by hydrogen bonding between 
the backbone N-H group on one strand to the backbone C=O group on the adjacent 
strand, as well as other intramolecular forces such as hydrophobic interactions305. The 
nature of the interactions explains why so many different protein structures can adopt the 
amyloid fibril confirmation. Amyloid fibrils have been implicated in numerous 
neurodegenerative diseases such as AD, Parkinson’s disease and Creutzfeldt-Jakob 
disease just to name a few. The formation of amyloid fibrils from native protein folds is 
not completely understood, yet it is commonly accepted that the process is a nucleation 
driven event and when one protein adopts the amyloidogenic fold, it can re-fold other 
native proteins into amyloid structures229. The amyloid structures will aggregate as more 
are formed and begin to oligomerize and continue aggregating forming the insoluble 
fibrillar structure. 
In an effort to understand and inhibit the process of amyloid fibril formation, research has 
investigated inhibitors of fibril formation and disassembly agents to reduce the 
concentration of fibrillar protein deposits. To investigate the inhibition of fibril formation 
or disassembly, we must first generate amyloid fibrils in vitro. Although strongly protein 
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dependent, traditionally, the methods for fibril formations prioritized acidic conditions, 
preferably pH 1.5-2.5 and elevated temperatures which generate fibrillar species without 
the need for sample agitation306,307. Acidic and elevated temperature conditions help 
break apart the tertiary and secondary structure of a protein without denaturing the 
sample228. The protein is then free to re-arrange to a new lower energy conformation, 
which, for these proteins, results in the formation of amyloid fibrils. While many 
publications on amyloid fibril disassembly compounds rely on these in vitro generated 
protein structures, very little is known about how they compare to in vivo fibril species. It 
is well documented that amyloid fibril formation can result in slightly different structures 
depending on growth methodology304. Several studies have investigated generating 
amyloid fibrils in concentrated ethanol solutions308 and under physiological pH with 
shaking239. However, many of these reports are not consistent, with different conditions 
reported between labs, to provide reproducible fibril formation. The fibril formation, 
when performed as an assay for finding suitable inhibitors of the process for drug 
development, should have parameters that mimic physiological conditions. Acidic and 
physiological growth conditions may have different impacts on fibril formation and drug 
stability. This section aims to investigate several methods for growing amyloid fibril 
species of lysozyme309,310 and insulin and comparing the fibril species generated to their 
counterparts generated in acidic conditions. Specifically, the lysozyme project looks to 
investigate fibril formation conditions that could easily be replicated in a teaching lab 
setting for students to work with an AFM, while the insulin project aims to develop a 
reliable assay for fibril development under physiological pH for use in future drug 
development. 
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10.2 Results 
10.2.1 Lysozyme 
In order to investigate lysozyme amyloid fibril formation for the development of an upper 
level biochemistry lab, lysozyme fibrils were grown in various concentrations of (50% to 
90%) ethanol. The goal was to generate lysozyme fibrils reproducibly and in a way that 
fits the time-frame and schedule of the laboratory exercises. Samples (1.0 mL) were 
incubated at room temperature with constant agitation with a magnetic stir bar. The 
samples were monitored for amyloid fibril formation for one and two weeks through ThT 
fluorescence intensity and AFM. The amount of fibril formation increased with the 
percentage of ethanol in the solution according to the ThT data for seven and fourteen 
days of incubation (Tables 17 and 18).  
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Table 17: ThT intensity and AFM dimension values of lysozyme fibrils grown in 
concentrated ethanol solutions after 7 days. 
 
 
Table 18: ThT intensity and AFM dimension values of lysozyme fibrils grown in 
concentrated ethanol solutions after 14 days. 
 
 
However, the AFM results suggest that the percentage of ethanol in the solution has a big 
impact on the size of the amyloid fibrils, not just their quantity. Ethanol at an 80% 
concentration was identified as the most consistent and simplistic procedure to generate 
amyloid fibrils by this method.  
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Fig. 63: Representative AFM images of prepared lysozyme samples after 7 days of 
incubation. a) 2 μm x 2 μm scan of lysozyme fibril formed under 50% ethanol 
concentration b) 5 μm x 5 μm scan of lysozyme fibril formed under 70% ethanol 
concentration c) 5 μm x 5 μm scan of lysozyme fibrils formed under 80% ethanol 
concentration d) 5 μm x 5 μm scan of lysozyme fibrils formed under 90% ethanol 
concentration. 
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Fig. 64: Representative AFM images of prepared lysozyme samples after 14 days of 
incubation. a) 2μm x 2μm scan of a lysozyme fibril formed under 50% ethanol 
concentration b) 2μm x 2μm scan of a lysozyme fibril formed under 70% ethanol 
concentration c) 5μm x 5μm scan of lysozyme fibrils formed under 80% ethanol 
concentration d) 5μm x 5μm scan of lysozyme fibrils formed under 90% ethanol 
concentration 
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Fig. 65: Representative AFM images of denatured lysozyme samples (A: 256 x 256 pixel 
resolution, C: 512 x 512 pixel resolution) compared to the 80% ethanol sample after 14 
days of incubation (B: 256 x 256 pixel resolution, D: 512 x 512 pixel resolution).  
 
A control of denatured lysozyme was used as a comparison to show that the fibrillar 
species identified were unique and not just denatured protein. 
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10.2.2 Insulin 
Insulin fibrils are typically grown under acidic (pH 1.6) and high temperature (70 °C) 
conditions. However, the results of fibril formation inhibition and disassembly studies 
using acidic conditions may not represent amyloid fibril species generated under 
physiological conditions. In addition, the classical form of the inhibitors/disassembly 
agents could be altered under strong acidic conditions (e.g. protonation, decomposition, 
etc.). To identify variations in insulin amyloid fibril formation, the protein was processed 
through the following conditions: acidic (1.6 pH and 70 °C)240, physiological (PBS and 
37 °C), physiological with shaking (PBS and 37 °C at 300 rpm), physiological with 
shaking and high temperature(PBS and 70 °C at 300 rpm) and physiological pH and 
temperature containing a Teflon bead with shaking (PBS and 37 °C at 700 rpm). The data 
are tabulated in Table 19.  
 
Table 19: ThT intensity values of insulin fibrils grown in various conditions. The ThT 
values were followed for at most four days. 
 
The results of the ThT studies for the insulin fibril formation under different growth 
conditions can be seen in Table 19 and representative ThT spectra can be seen in 
appendix - A. The results from these experiments concluded that under physiological pH 
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conditions insulin forms fibrillar species in the presence of a nucleation agent, such as a 
Teflon bead. The acidic procedure provided the highest fibril content seen in this study. 
However, as the goal in this case was to investigate optimal conditions for fibril 
inhibition studies, the physiological pH conditions are promising. Under these conditions, 
amyloid fibril formation did not occur unless there was a nucleation agent present in the 
sample (such as a bead, or fibril seeding). AFM images for the acidic and physiological 
pH sample with the Teflon ball can be seen in Figs. 66 and 67. 
 
Fig. 66: Representative AFM image of prepared insulin fibrils after 3 days of incubation 
in PBS and 37 °C with shaking at 700 rpm and the addition of a 1/8 in. diameter Teflon 
bead. 
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Fig. 67: Representative AFM image of prepared insulin fibrils after 4 days of incubation 
under acidic conditions and 70 °C with shaking at 300 rpm. 
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10.3 Discussion 
Lysozyme 
The ThT intensities were recorded after one week for the lysozyme samples grown in 
ethanol solutions. The fluorescence intensity and AFM dimensions of the lysozyme fibril 
samples increased as the concentrations of ethanol increased, as can be seen in Tables 17 
and 18, suggesting that amyloid fibril formation was occurring quicker in the solutions 
with higher concentrations of ethanol as a solvent. This was corroborated by the AFM 
data seen in Fig. 63. The generation of amyloid fibrils has increased for lysozyme sample 
preparation in the 80% and 90% ethanol (Fig. 64). Readings of ThT fluorescence were 
collected at week two to determine if the amyloid fibril growth continued for all samples. 
The data recorded after fourteen days of incubation of lysozyme in concentrated ethanol 
solutions further exemplifies the fact that lysozyme forms fibrils under these conditions. 
The fluorescence intensity and AFM dimensions of the lysozyme fibril samples increased 
from the previous week for all samples except the 90% ethanol as can be seen in Table 18 
and Fig. 64. It was observed that the 80% and 90% ethanol AFM images, seen in Fig. 64, 
look very similar and yet the ThT intensities are drastically different. This is likely 
because the 90% ethanol solution has a greater density of amyloid fibrils than what can 
be seen in the 80% ethanol sample. This can cause scattering of the fluorescence light 
produced by exciting the bound ThT due to the large number of fibril species in solution, 
providing a lower fluorescence intensity than what would be expected. The lysozyme 
fibril formation in 80% ethanol was concluded to be the best representation of fibril 
growth for this study. Heat denatured lysozyme samples were used as a control to ensure 
that the species present in the AFM images was not just denatured lysozyme. As can be 
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seen in Fig. 65, the heat denatured lysozyme does not resemble the ordered structures that 
can be seen for the fibrils formed in the concentrated ethanol solutions. 
Insulin 
The insulin samples were prepared under different conditions. The aim of this work was 
to investigate and compare the growth of insulin amyloid fibrils under acidic and 
physiological conditions. The results from this experiment concluded that under 
physiological conditions insulin may not be able to form fibrillar species at 37 °C and at 
70 °C it may denature. Insulin fibrils were readily formed after four days of incubation at 
37 °C with shaking at 700 rpm under physiological pH conditions. The important factor 
that helped the growth of the amyloid fibrils was the addition of a nucleation agent, a 1/8 
in. diameter Teflon bead. Examples of the fibril formation analyzed by AFM can be seen 
in Fig. 66. The acidic procedure also provided the highest fibril content seen in this study, 
but the fibril species were distinctly different than those identified in the physiological 
pH samples (Fig. 67).  
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CHAPTER 11 
CONCLUSIONS 
 
The above detailed description and analysis of the collected data allowed me to draw 
several major conclusions from my studies. The major findings of my work are as 
follows. 
11.1 β-carbolines as multi-functional drug candidates 
We have identified β-carbolines as promising drug candidates for further development of 
multi-functional AD therapeutics. The most promising compound that could serve as lead 
for drug discovery would be compound 10. Having 40% Aβ fibril formation inhibition 
activity and an EC50 value of 110 µM, and oligomer formation inhibition activity of 58% 
highlights the compounds ability to not only inhibit the formation of Aβ fibrils, but to 
prevent the buildup of the toxic oligomeric species as well. The selectivity for 
butyrylcholinesterase for all of the β-carbolines (IC50 = 225 ± 30 nM for compound 10) 
coupled with the strong activity in scavenging of peroxyl radicals suggests these 
compounds are excellent candidates for further multi-target drug development for AD.  
11.2 Hydrazide and nipecotic acid derivatives as multi-functional drug candidates 
I have contributed to a collaborative work on hydrazide and nipecotic acid derivatives 
investigated as cholinesterase inhibitors. These derivatives were identified through 
computer aided drug discovery19. The aim is to develop drugs based on the molecular 
interactions expected to occur at the active site of an enzyme so that the drug will bind 
efficiently and fit into the protein. Fourteen compounds were developed based on the 
docking studies, mimicking the electrostatic interactions of donepezil. While the 
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compounds did not retain significant activity in the in vitro assays, they were identified as 
potential radical scavenging compounds. Compounds 17, 20 and 22 had the highest 
radical scavenging activity in the ORAC assay with scavenging values of 88%, 80% and 
56%. Development of these compounds should be continued, with an emphasis on 
understanding why they were not functional inhibitors. The fact that they showed radical 
scavenging activity suggests that they may be useful in the development of multi-
functional drug candidates. 
11.3 SAR study of hydrazones as radical scavenging agents 
The results from the hydrazone radical scavenging SAR identifies clear and firm 
relationships between the structural and energetic features (BDE, ionization potential and 
logP) and their contribution to radical scavenging activity. Compound 43, which 
possesses a structure with no N–H bond, uniformly did not exhibit any measurable effect 
highlighting the importance of the N-H bond for radical scavenging activity. The rest of 
the hydrazones were most active against the smallest peroxyl radical used in the ORAC 
assay surpassing the activity of the controls with activity values ranging from 50 to 88%. 
The linear correlation of the ORAC (R2=0.6505) and DPPH (R2=0.6081) data with the 
BDE suggests the compounds react through the HAT mechanism, via homolytic bond 
cleavage and the H atoms scavenge the radical species. The trend between ionization 
potential and the ORAC data also suggests the radical scavenging by hydrazones is 
partially due to their participation in the single electron transfer (SET) mechanism. The 
SAR correlation with logP suggests that the scavenging activity improved with increasing 
hydrophobicity. The results of this SAR study highlight common notions seen in the 
literature where BDE294-296 and IP226,229 are generally correlated with antioxidant activity. 
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An extended study with a broader group of hydrazones bearing more diverse substituents 
is needed to propose a quantitative description of the effect of these features that would 
make possible the rational design of antioxidants for potential therapeutic use. 
11.4 SAR study on radical scavenging activity of phenol and aniline model 
compounds 
Based on the SAR study with hydrazones in Chapter 7, it was decided to analyze the 
radical scavenging activity of phenol and aniline models as a function of their calculated 
properties. The goal was to provide a better understanding of the contributing factors on 
the radical scavenging capabilities of these compounds. It was observed that phenols, on 
average, possess higher radical scavenging activity than anilines. However, several 
anilines showed much higher activity than the majority of phenols, thus the activity 
ranges overlap, indicating that anilines are comparable radical scavengers to phenols. 
Regarding phenols, it has been found that increasing the number of -OH groups does not 
necessarily result in parallel enhancement in radical scavenging activity. It was observed 
however, that the position of the multiple -OH groups is of particular importance; having 
them in 1,3 position results in significant synergistic increase in activity, in contrast to 1,2 
or 1,4-positions.   The study identified several physical properties that likely govern the 
free radical scavenging activity of both phenols and anilines, such as the HOMO 
energies, band gap and BDE. Anilines, on the other hand, appear to act via more complex 
pathways as the ionization potential, dipole moment and proton affinity all have 
considerable effect on their radical scavenging properties. 
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11.5 Hydrazones as multi-functional drug candidates 
Hydrazones, which have already been studied as potential anti- AD agents, were 
investigated for their potential function as CK2 holoenzyme inhibitors to treat cancer. 
The hydrazones from Chapter 7 were investigated and determined to have promising 
activity against the CK2α’ monomer of CK2. Compounds 31, 36, 37, 38, 40, 42 and 45 
were determined to have IC50 values from 1 to 15 µM. It was observed that hydrazones 
with halogen, particularly fluorine, were good inhibitors of CK2α’. This information 
served as a foundation and led to the design and synthesis of phase 2 hydrazone 
derivatives which include more fluorines. The phase 2 hydrazones exhibited different 
radical scavenging profiles than their phase 1 counterparts; with the ABTS and DPPH 
activity profiles of these compounds increased and the ORAC activity was ultimately 
lower and less uniform than that of the phase 1 compounds. This work is still in progress 
and the full profile determination of these hydrazones as CK2 inhibitors is currently 
underway. 
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11.6 Optimization of the conditions for the formation of amyloid fibrils 
It is clear from our work that conditions maintained during amyloid fibril formation are 
crucially important. When generating amyloid fibril species, the protein in question needs 
an environment that is unfavorable to its natively folded state in order to initiate the 
protein to adopt the amyloid state. In addition, when the fibril formation is performed as 
an assay for finding suitable inhibitors of the process for drug development purposes it is 
important that the parameters mimic physiological conditions. In practice, one has to 
consider the goal of an assay and optimize the conditions accordingly. During my work I 
optimized the fibril formation process of two amyloidogenic proteins: lysozyme and 
insulin. Lysozyme fibril formation optimization was investigated to provide fibril 
formation conditions that could easily be replicated in a teaching lab setting for students 
to work with an AFM. Since the lysozyme project was not investigating self-assembly 
inhibitors, the conditions for amyloid fibril formation did not need to be physiological. I 
was also able to optimize the formation of insulin amyloid fibrils under physiological 
conditions which required the facilitation of the seeding in the sample. As amyloid fibril 
formation is already understood to be a nucleation driven process229 this is in agreement 
with earlier findings regarding other proteins. The differences in fibril structure seen 
between the acidic and physiological pH preparation methods clearly show the 
importance of investigations on amyloid fibril formation prior to studying self-assembly 
inhibitors and disassembly agents. My optimized protocol will allow the testing of insulin 
self-assembly inhibitors under physiological pH and temperature. 
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APPENDIX 
A. SELECTED THIOFLAVIN T EMMISSION SPECTRA FOR INSULIN FIBRIL 
FORMATION 
 
ThT emission spectra for insulin fibrils formed under acidic conditions after 2 days. (red: 
insulin + ThT, blue: ThT, black: insulin) 
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ThT emission spectra for insulin fibrils formed under physiological conditions at 37 °C 
and 300 rpm after 3 days. (red: insulin + ThT, blue: ThT, black: insulin) 
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ThT emission spectra for insulin fibrils formed under physiological conditions at 70 °C 
and 300 rpm after 3 days. (red: insulin + ThT, blue: ThT, black: insulin) 
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ThT emission spectra for insulin fibrils formed under physiological conditions at 37 °C, 
700 rpm and a Teflon ball added after 3 days. (red: insulin + ThT, blue: ThT, black: 
insulin) 
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B. PLOT OF BDE ENEGRY VS. RADICAL SCAVENGIN ACTIVITY FOR SAR OF 
HYDRAZONES 
  
ORAC radical scavenging activity vs. BDE plot to illustrate the effect of the BDE on the 
activity of all hydrazones investigated in the SAR study. 
 
DPPH radical scavenging activity vs. BDE plot to illustrate the effect of the BDE on the 
activity of all hydrazones investigated in the SAR study. 
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